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Adalimumab treatment for moderate to severe psoriasis substantially improves PASI scores
as analyzed by body region and individual PASI component: Sub-analysis from the CHAM-
PION study
AA Navarini,1 Y Poulin,2 Y Gu3 and HD Teixeira3 1 University Hospital Zurich, Zurich,
Switzerland, 2 Centre Dermatologique du Quebec Metropolitain, Quebec, QC, Canada and
3 Abbott, Abbott Park, IL
To compare the efficacy of adalimumab (ADA) vs. methotrexate (MTX) in improvement of Psoria-
sis Area and Severity Index (PASI) scores for specific body regions and individual PASI components.
In this 16-week randomized controlled trial, patients (pts) with moderate to severe psoriasis were
randomized (2:2:1) to ADA (80 mg/Wk 0, 40 mg every other week/Wks 1-15), MTX (7.5 mg up to
25 mg weekly), or placebo (PBO). Post hoc analyses evaluated mean percent changes in PASI scores
by body regions and by PASI components. Each component-specific PASI was defined as a weighted
average across body regions: 10%, 20%, 30% and 40% for head, upper extremities, trunk, lower
extremities, respectively. PASI score for each region was the sum of scores for PASI components
erythema, induration, desquamation multiplied by the area of involvement score for the corre-
sponding region. Missing data were imputed using last observation carried forward. ANOVA ana-
lyzed treatment difference of ADA vs. MTX and PBO in the intent to treat (ITT) population (all ran-
domized pts). ITT population included 271 pts (ADA n=108; MTX n=110; PBO n=53). Mean percent
changes from baseline to Wk 16 in PASI scores by body region for ADA/MTX/PBO-treated pts were:
81.3%/56.9%/26.9% head; 85.6%/51.4%/19.6% trunk; 79.0%/52.8%/15.0% upper extremities;
and 77.8%/52.5%/14.9% lower extremities. Mean percent changes from baseline to Wk 16 in PASI
scores by PASI components were: 78.3%/52.3%/21.0% erythema; 81.7%/56.3%/22.3% induration;
81.4%/52.8%/18.5% desquamation; and 63.5%/35.2%/12.0% area. All percent change compar-
isons were statistically significant at P<.001. Compared to MTX and PBO, ADA provided substan-
tial improvements in PASI scores for all body regions and individual PASI components. There was
similar improvement across body regions and individual PASI components.
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Sequential therapy with oral tacrolimus and topical tacrolimus as an effective and safe treat-
ment for generalized atopic dermatitis: A pilot study
T Keaney, JW Wong and J Koo Dermatology, University of California San Francisco, San
Francisco, CA
Atopic dermatitis (AD) is a chronic skin disorder that affects 10-20% of children and up to 3% of
adults. In the past two decades, unlike psoriasis, no new treatment options have been developed
for generalized AD, while new treatment options for psoriasis including many biologic agents,
excimer laser, and narrowband ultraviolet B therapy, to name a few, became available. Meanwhile,
many patients with severe, generalized AD use systemic steroids, which are not recommended for
long term use secondary to serious potential steroid side effects such as obesity, osteoporosis, and
hypertension. Beyond steroids, new systemic treatment options for generalized AD are needed.
There have been no prospective trials investigating the use of oral tacrolimus in AD. We evaluated
the efficacy and safety of sequential use of oral tacrolimus followed by topical tacrolimus in the
treatment of generalized AD. We performed an open-label, single center, proof of concept prospec-
tive study of twelve patients with generalized AD covering at least 50% body surface area. Subjects
received sequential therapy starting with oral tacrolimus and transitioning to topical tacrolimus over
a 14-week treatment period. Eczema Area and Severity Index (EASI), Physician’s Global Assessment
(PGA), and pruritus scores were obtained. We found a 67% improvement in the EASI score, 45%
improvement in the PGA score, and 69% decrease in pruritus score. Adverse effects were minimal.
This is the only study that evaluates the efficacy and safety of oral tacrolimus as a possible treat-
ment for AD. The results of this study suggest that oral tacrolimus can be an effective and safe short-
term treatment option for severe, generalized AD and can be transitioned to topical tacrolimus
smoothly. More studies are needed to confirm our findings.
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Natural modulation of PAR-2 and TLR2: Application to clinical acne skin care
N Lachmann,1 C Baudouin,1 M Biassette,1 S Bredif,1 F Menu,1 B Chadoutaud,2 P Msika1 and
B Cribier3 1 Innovation R&D, Laboratoires Expanscience, Epernon, France, 2 ClinReal,
Toulouse, France and 3 Dermatological Clinic, Louis Pasteur University, Strasbourg, France
Inflammation plays a central role in acne. A global acne skin care product has been formulated
with active principles: Quinoa peptides (natural PAR-2 modulator), 5-alpha avocuta, zinc gluconate,
capryloyl glycine and long lasting alpha hydroxy acid derived. In vitro studies on 5-alpha avocuta
In dermal fibroblasts, it significantly inhibited type 1 5-alpha reductase activity (-49%). In ker-
atinocytes treated with a synthetic TLR2 (Toll Like Receptor) ligand mimicking P acnes lipoprotein,
it reduced the TLR2 gene overexpression (-52%), contributing to counteract the P.acnes-induced
inflammatory cascade. Quantification of UV P acnes derived porphyrines fluorescence 22 acneic
patients, aged 11 to 40, applied the tested product twice a day for 30 days during an open study.
VISIA CR coupled to computerized analysis demonstrated a 30% decrease of bacterial activity. Clin-
ical study A single blind comparative randomized study performed under dermatological control
included 126 female patients (15-35 years old) with light to moderate acne (≤12 retentional and 5
to 9 inflammatory lesions). 64 applied tested product and 62 a referenced product twice daily for
90 days. There were no statistic difference between both groups at D45 and D90. Tested product
decreased inflammatory (respectively -50% and -70.3%) and retentional (-40.2%/-57.3%) lesions
(p<0.01). Investigator Global Assessment (IGA) confirmed an improvement in 89% of patients, 79.6%
≥ 50%. Seborrhea and post-lesional erythema were reduced by 38.5% and 35.1% at D45 (p<0.01)
and by 56.4% and 51.4% at D90 (p<0.01). Tolerance was excellent in 98% of cases. The use of a
product targeting key acneic pathways (inflammation receptors, hyperseborrhea, hyperkeratinisa-
tion) with active principles from natural technology leads to a significant global improvement in
mild to moderate acne.
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Modulating vascular inflammation and immune immunity: A new generation of anti-redness
skin care
C Baudouin,1 N Lachmann,1 J Rocheteau,1 M Biassette,1 S Bredif,1 F Menu,1 P Msika1 and
G Lorette2 1 Innovation R&D, Laboratoires Expanscience, Epernon, France and 2 Dermatology,
Trousseau Hospital CHRU, Tours, France
Altered innate immune response plays a central role in the pathogenesis of different sub-types of
rosacea. A natural Anti-Redness (AR) skin care has been formulated with patented active principles
from natural technology, to modulate PAR-2, restore skin barrier function, decrease aspecific and
neurogenic inflammation (Lupine peptides: LU), and to regulate innate immunity and vascular fac-
tors (Arabinogalactane: AR). In vitro studies of the association AR+LU: In calcitriol-stimulated nor-
mal human epidermal keratinocytes (NHEK), it reduced the gene overexpression of Kallikrein 5 (-
39%) and LL37 (-53%) (QPCR) and significantly decreased the IL-8 release (-33%, ELISA). AR+LU
significantly slowed down VEGF-stimulated proliferation of human dermal microvascular cells at
24h (-50%) and 48h (-25%). Vascular and extracellular matrix molecules’ gene expression has
been regulated in NHEK (VEGF: -87%; HIF1alpha: -54%; MMP-2: -47%). During a single-blind
study, 30 women with sensitive skin and erythemato-telangiectatic rosacea applied AR skin care
twice daily for 55 days, followed by a placebo for 15 days. Product normalized skin perfusion unit
at T55 (-52% erythema vs T0 on treated area, no statistical difference vs healthy skin). A statistical
decrease in the mean intensity of the vascularization was observed at T27 (-4.9%), T55 (-9.2%) and
T69 (-15.8%). A significant decrease in the mean score (treated-control) was observed at T27, T55
(-33%) and T69. Clinically, diffuse erythema was reduced at T27 and T55 among 57% and 67% of
patients telangiectasia by 32% and 48% and sensitive skin sensations in 68% and 78% of patients.
Thanks to its active principles specifically dedicated to control molecular pathways involved in
sensitivity and redness skin troubles, a new AR formulation has demonstrated a significant improve-
ment in facial redness.
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Neutralization of IL-17A with LY2439821 compared to TNF with etanercept: effects on inflam-
matory gene expression underlying psoriasis pathogenesis
J Krueger,1 S Fretzin,2 M Suárez-Fariñas,1 P Haslett,3 K Phipps,3 G Cameron,3 J McColm,3
A Katcherian,1 I Cueto,1 T White,1 S Banerjee3 and R Hoffman3 1 Rockefeller University, New
York, NY, 2 Dawes-Fretzin, Indianapolis, IN and 3 Eli Lilly and Company, Indianapolis, IN
Neutralization of TNF is effective in improving psoriasis, and some evidence suggests that this
effect may be due to reduction in IL-17A (IL-17) expression. In this analysis, we compare the early
effects (prior to the onset of a full clinical response) of TNF and IL-17 neutralization on gene expres-
sion in inflammatory pathways underlying psoriasis from Week 0 (pre-dose) to 2 of treatment, using
whole genome microarray data of lesional skin biopsies from patients treated with etanercept or an
anti-IL-17 monoclonal antibody, LY2439821. Gene expression data for patients treated with
LY2439821 were obtained from a phase 1, randomized, double-blind, placebo-controlled trial in
which patients received 3 subcutaneous doses of 150 mg of LY2439821 (n=8) at Weeks 0, 2 and 4.
All patients achieved a PASI 75 at Week 6 with no unexpected safety signals in this study. Gene
expression data for patients treated with 50 mg etanercept (n=15) twice weekly for 12 weeks were
obtained from a publicly available repository. After normalizing the data for a batch effect, LY2439821
showed a greater impact than etanercept on the expression of inflammatory genes known to be asso-
ciated with psoriasis. Of these inflammatory genes, 643 showed >75% normalization after LY2439821
treatment compared to 104 after etanercept treatment (p<0.001). In addition, LY2439821 treatment
improved the expression of genes regulated by IL-17, IL-22, TNF and IFN-γ more than etanercept,
as well as those genes known to be co-regulated (additively and synergistically) by IL-17 and TNF
(p<0.001 for all comparisons). In this analysis, neutralization of IL-17 had a greater impact than TNF
neutralization on signaling through pathogenic inflammatory circuits in psoriasis at 2 weeks, and
this suggests that IL-17 may be a central cytokine driving pathogenic inflammation in this disease.
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The efficacy of acyclovir 5%/ hydrocortisone 1% cream by age: Post hoc analysis
CM Hull,1 R Gordon,2 JT Olin3 and SK Tyring4 1 University of Utah, Salt Lake City, UT, 2 Center
for Clinical Studies, Houston, TX, 3 Valeant Pharmaceuticals North America LLC, Bridgewater,
NJ and 4 The University of Texas Medical School at Houston, Houston, TX
Acyclovir (AC) 5%/hydrocortisone 1% cream (AHC) is an effective treatment for recurrent herpes
simplex labialis (HSL); however, its effects across age groups have not been assessed. In this trial
(Medivir study 609-04; NCT00361881), patients with a history of recurrent HSL were randomized
to self-initiated AHC, AC, or vehicle at the earliest signs of recurrence. Of 2437 individuals ran-
domized, 1443 experienced a recurrence and received ≥1 dose of study medication (601 AHC,
610 AC, 232 vehicle). Ulcerative recurrences were those leading to development of a lesion that
underwent vesicle, ulcer/soft crust, and/or hard crust formation. Here, we report recurrence rates
and mean episode durations by age group (18-37 years, N=501; 38-57 years, N=704; 58-80 years,
N=238) using descriptive statistics. The rates of nonulcerative recurrences with AHC in the youngest
(37.1% [79/213]), middle (43.2% [127/294]), and eldest (51.1% [48/94]) groups were lower, com-
pared with the groups treated with AC (28.8% [61/212], 38.2% [113/296], 41.2% [42/102], respec-
tively) and vehicle (26.3% [20/76], 28.1% [32/114], 19.0% [8/42]). For the youngest, middle, and
eldest groups, the mean episode durations for any recurrence (ulcerative or nonulcerative) were 5.6,
5.4, and 5.2 days with AHC, respectively; 5.7, 5.3, and 5.7 days with AC; and 5.9, 5.6, and 7.0
days with vehicle. For nonulcerative recurrences, mean episode durations with AHC were 5.5, 4.8,
and 4.8 days in the youngest, middle, and eldest groups, respectively; 5.1, 4.5, and 5.1 days with
AC; and 4.0, 4.5, and 4.0 days with vehicle. This post hoc analysis suggests that the effect of AHC
on preventing ulcerative HSL recurrences may increase with age and may be greater than the AC
effect across adult age groups. However, age does not appear to play a role in episode duration,
regardless of treatment or recurrence type.
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Stimulation of procollagen production by cosmeceuticals is dependent on low initial level of
procollagen in photoaged human skin
D Sachs, L Rittie, H Chubb, J Orringer, G Fisher and J Voorhees Dermatology, University of
Michigan, Ann Arbor, MI
Cosmeceuticals are widely available for the treatment of aging skin, but data are lacking regarding
their ability to induce molecular responses associated with wrinkle effacement, such as type I pro-
collagen (COL) production. Therefore, we determined the ability of five readily available cosme-
ceuticals (purchased by University of Michigan Department of Dermatology) to increase produc-
tion of COL, in human photodamaged forearm skin. Each cosmeceutical contained a distinct main
ingredient: vitamin C, pentapeptide, alpha lipoic acid, yeast extract or 1% idebenone. A single cos-
meceutical was applied daily, unoccluded, to photodamaged forearm skin for two to three weeks.
Punch biopsies were obtained pre and post-treatment and analyzed for COL by ELISA. Ninety-one
subjects completed the five independent studies and data were submitted to retrospective statisti-
cal meta-analysis. Baseline COL levels across all studies ranged from 1.8-43.7 ng/mm3. Low base-
line procollagen level (defined as ≤12.6 ng/mm3) was the only factor that influenced whether sub-
jects responded to cosmeceuticals. For example, following topical vitamin C, subjects with “low”
baseline procollagen demonstrated a significant 2.0 ± 0.4-fold increase of COL (n=9, p<.05), com-
pared to subjects with “high” baseline procollagen (defined as ≥16.4 ng/mm3) who had no COL
change (0.95±0.19-fold, n=10, p>.05). Sixty-five percent of all subjects with “low” baseline pro-
collagen showed statistically significant increase of procollagen while only 22% of subjects with
“high” baseline procollagen showed improved procollagen content. Age and gender had no effect
on response. These studies reveal that responders to cosmeceuticals tend to have low baseline col-
lagen levels. This finding is significant for design of future studies of topical agents and devices for
their ability to enhance collagen content of dermis.
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The pleasurability of scratching an Itch: A psychophysical and topographical assessment
SG Kwatra,1 GA bin Saif,3 AD Papoiu,1 F McGlone,4 Y Chan5 and G Yosipovitch1,2 1 Dermatology,
Wake Forest University School of Medicine, Winston-Salem, NC, 2 Neurobiology & Anatomy,
Wake Forest University School of Medicine, Winston-Salem, NC, 3 Dermatology, King Saud
University College of Medicine, Ryadh, Saudi Arabia, 4 School of Natural Sciences and
Psychology, John Moores University, Liverpool, United Kingdom and 5 Biostatistics Unit, Yung
Loo Lin School of Medicine, Kent Ridge, Singapore
Scratching an itch is pleasurable. However, an analysis of topographical variations in itch intensity,
the effectiveness of scratching to provide itch relief and the associated pleasurability has not been
performed at different body sites. To examine the role of scratching pleasurability in providing itch
relief by investigating whether itch intensity is perceived differently at 3 different sites and to assess
a potential correlation between the pleasurability and itch attenuation induced by scratching.
Eighteen healthy subjects had itch induced by cowhage on the forearm, ankle and back. These sites
were subsequently scratched by an investigator with a cytology brush immediately following itch
induction. The intensity of itch with and without scratching at these sites and the pleasurability of
scratching were recorded by taking VAS ratings at 30 seconds interval. Average itch intensity and
scratching pleasurability ratings at the ankle and back were significantly higher than on the fore-
arm. For the forearm and ankle, the higher the itch while scratching, the higher was the pleasura-
bility. A higher baseline itch was linked to a higher itch reduction secondary to scratching in all
tested areas. Pleasurability paralleled the curve of itch reduction for the back and forearm, however
scratching pleasurability at the ankle remained elevated and only slightly decreased while itch was
diminishing. There are topographical differences in itch intensity, the effectiveness of scratching in
relieving itch and the associated pleasurability. Itch was more intensely perceived at the ankle
while scratching attenuated itch most effectively on the back.
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BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
H Vin,2 ML Leung,2 V Chitsazzadeh,2 S Ojeda,2 DW Dwyer,2 KN Richards,2 LR Stewart,2 JL Curry,3
K Kim,4 AM Ciurea,1 M Duvic,1 VG Prieto,3 SE Ullrich,2 ER Flores5 and KY Tsai1,2 1 Dermatology,
MD Anderson Cancer Center, Houston, TX, 2 Immunology, MD Anderson Cancer Center,
Houston, TX, 3 Pathology, MD Anderson Cancer Center, Houston, TX, 4 Melanoma Medical
Oncology, MD Anderson Cancer Center, Houston, TX and 5 Biochemistry & Molecular
Biology, MD Anderson Cancer Center, Houston, TX
BRAF mutations are found in over 50% of melanomas and thyroid carcinomas, resulting in ele-
vated kinase activity, increased mitogen-activated protein kinase (MAPK) pathway signaling, and
proliferation. Vemurafenib and PLX4720 were designed to selectively inhibit the BRAF kinase, and
clinical trials of vemurafenib in metastatic melanoma demonstrated response rates of over 50%
that correlated with suppression of ERK signaling and an overall survival advantage over dacarbazine
therapy. Approximately 20-30% of individuals treated with vemurafenib develop cutaneous squa-
mous cell carcinoma (cSCC). Although the prevailing hypothesis for this is paradoxical ERK activa-
tion in the presence of mutant RAS, this is likely an incomplete explanation. Here we show an unex-
pected and novel effect of vemurafenib and PLX4720 in suppressing apoptosis through the inhibition
of multiple off-target kinases upstream of JNK. We found that these compounds suppress apoptosis
by inhibiting JNK signaling in-vitro and in-vivo. JNK signaling and apoptosis are suppressed in cSCC
lesions arising in vemurafenib-treated patients as well as in irradiated mouse skin, and drug-treated
mice develop tumors with decreased latency without a need for RAS mutation. These effects occur
independently of paradoxical ERK activation, and knockdown of the off-target kinases inhibited by
vemurafenib recapitulates the suppression of apoptosis and JNK signaling. Our results implicate
suppression of JNK signaling, independent of the ERK pathway, as a complementary mechanism of
adverse effects of vemurafenib. This has broad implications for combination therapies with other
modalities that induce apoptosis and for the long-term use of vemurafenib in the adjuvant setting.
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Disease activity and quality of life in refractory cutaneous lupus erythematosus patients
AY Chang,1,2 E Ghazi,1,2,3 J Okawa1,2 and VP Werth1,2 1 VAMC, Philadelphia, PA, 2 Derm, UPenn
School of Medicine, Philadelphia, PA and 3 UMDNJ-RWJ Medical School, Piscataway, NJ
Immunosuppressives are used as systemic therapy for antimalarial-refractory cutaneous lupus ery-
thematosus (CLE), despite limited evidence. This longitudinal cohort study prospectively evaluated
response to immunosuppressives in CLE patients using a validated disease outcome measure, the
CLE Disease Area and Severity Index (CLASI), and a validated skin-specific quality of life measure,
the Skindex-29. Eligible patients presented from Jan 2007 to Jul 2010 at a cutaneous autoimmune
disease clinic, met criteria for having CLE, and had at least 2 visits with CLASI activity scores meas-
ured. Those initiated on methotrexate, mycophenolate, or azathioprine with pre- and post-Tx CLASI
scores were identified. Patients who had previously failed an antimetabolite or non-antimalarial sys-
temic therapy were excluded. Response was defined as either a 4-point or 20% decrease in CLASI
score and was determined by comparing scores at the pre-Tx and first post-Tx visit. Of 5 patients
initiated on methotrexate, 4 responded with a decrease in median (IQR) CLASI activity score from
24 (14-33) to 12 (5-17) (p=0.07). Of 4 patients initiated on mycophenolate, 2 responded with a
decrease in median (IQR) CLASI score from 4.5 (2.0-7.0) to 1.0 (0.0-2.0) (p=0.18). Of 4 patients ini-
tiated on azathioprine, 0 responded. For 6 responders out of 13 patients initiated on an antimetabo-
lite, the mean (95% CI) Emotions score decreased from 64.2 (32.5, 95.8) to 39.1 (18.5, 59.8) (p=0.04),
Functioning score decreased from 53.0 (26.8, 79.2) to 28.1 (10.6, 45.6) (p=0.07), and Symptoms
score decreased from 55.4 (31.1, 79.6) to 36.3 (20.3, 52.3) (p=0.07). For the 7 non-responders, the
mean (95% CI) Emotions, Functioning, and Symptoms score were unchanged. Half of CLE patients
with antimalarial-refractory disease responded to the addition of an antimetabolite. Response in dis-
ease activity was accompanied by an improvement in skin-specific quality of life measures.
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Healthy scalp has a reduced sensory thresholds to temperature, pain, itch and neurogenic
inflammation response
GA Bin Saif,1,2 A Alajroush,2 A Mcmichael2 and G Yosipovitch2,3 1 Dermatology Department,
King Saud University Medical College, Riyadh, Saudi Arabia, 2 Dermatology Department,
Wake Forest University School of Medicine, W-S, NC and 3 Neurobiology and Anatomy
Departments, Wake Forest University School of Medicine, W-S, NC
The scalp is a highly innervated structure; however, there is limited data on its sensory function
related to itch, pain and warmth thresholds, which are mediated by small C Nerve fibers. These
data may explain events in hair grooming practice, including hair damage and sometimes burn from
using high temperatures without scalp symptoms. 22 healthy participants were recruited. Subjects
underwent the following assessments at 3 sites: volar forearm, crown and occiput: Quantitative
thermo-sensory testing measuring warmth and heat pain sensation thresholds. Itch was evoked by
two methods using histamine Iontophoresis and by Cowhage spicules. Itch intensity was assessed
over 5 minutes for each stimulus. Mean and peak perfusions were recorded at baseline then repeated
3 minutes after itch induction. Subjects rated itch intensity using a Visual Analog Scale from 0 to
10. We noted a strikingly different warmth and heat pain thresholds between scalp and forearm
skin. Crown had higher warm threshold (47.6+-4.1 oC), followed by occiput (42.9+-4.2 oC) and
the least is forearm (34.5+-1.4 oC) (p<0.001). Crown (49.99+-0.043 oC) and occiput (49.6+-0.94
oC), had higher pain threshold than forearm (43.3+-3.4 oC) (p<0.001). Scalp had lower mean and
peak histamine- and cowhage-induced itch rating than forearm skin (p=<0.001). In addition, peak
itch rating of cowhage on occiput is higher than crown (p=0.017). Histamine and Cowhage induced
higher mean and peak skin blood flow changes on forearm in comparison to scalp (p=<0.001). In
conclusion, healthy Scalp C nerve fiber function differs significantly from other skin sites in both
thermal, pain and itch sensation and neurogenic inflammation response. These results suggest the
scalp as a unique neural skin entity. These results may have clinical implications. Future studies
examining the sensation in scalp diseases are warranted.
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Double-blind, randomized, bilateral comparison of skin irritancy following application of the
combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene
R Goreshi,1 A Samrao1,2 and BD Ehst1 1 Oregon Health and Science University, Portland, OR
and 2 Harbor-UCLA, Torrence, CA
We sought to compare the tolerability of two combination topical acne products, clindamycin 1.2%-
tretinoin 0.025% (CLIN/RA) gel and benzoyl peroxide 2.5%-adapalene 0.1% (BPO/RA) gel. The
use of topical medications for acne vulgaris is often limited by their irritant properties. Newer com-
bination preparations are available and offer convenience but irritant potential may still be a hin-
drance, perhaps more so with the addition of two agents. Few studies have compared these for-
mulations directly for tolerability. CLIN/RA and BPO/RA were applied daily to opposite sides of a
subject’s face for 21 days in a double-blinded fashion. Investigator and study subject self assess-
ments of burning/stinging, itching, erythema, and dryness/scaling were collected. Transepidermal
water loss (TEWL) was also measured as an objective measure of skin irritation. A mixed model
analysis and repeated measures ANOVA were used to compare outcomes for both acne formula-
tions. CLIN/RA produced significantly less burning/stinging than BPO/RA (p<0.001) as well as sig-
nificantly less pruritus than BPO/RA (p<0.001). BPO/RA caused significantly more TEWL than
CLIN/RA (p=0.005). There was no significant difference in the amount of erythema or the amount
of dryness/scaling caused by either formulation. In conclusion, CLIN/RA produced significantly
less skin irritancy and TEWL than BPO/RA.
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Phase I/II clinical trial of O6benzylguanine (O6BG)-potentiated topical carmustine (BCNU)
in the treatment of cutaneous T-cell lymphoma (CTCL)
JD Tacastacas,1 DV Chan,1 A Dowlati,2,3,4 SL Gerson,2,3,4 K Honda,1 K Lu,1,4 P Fu4 and
KD Cooper1,3,4 1 Dermatology, University Hospitals Case Medical Center, Cleveland, OH, 2
Internal Medicine, University Hospitals Case Medical Center, Cleveland, OH, 3 Case
Comprehensive Cancer Center, Cleveland, OH and 4 Case Western Reserve University,
Cleveland, OH
The objectives of this study were to determine the response rate and safety of BCNU when applied
biweekly with O6BG. Our initial Phase I trial indicated that responses were proportional to dura-
tion of inhibition of O6-alkylguanine DNA alkyltransferase (AGT) activity by O6BG in CTCL lesions
(NCI-T97-0029). We hypothesized that a second dose of O6BG would prolong AGT inhibition and
improve clinical response rates. This is an interim analysis of a single-arm clinical trial designed to
determine the maximum tolerated dose of a whole body application of BCNU after a fixed intra-
venous dose of O6BG on day 1 & 2 of each cycle. To date, we have screened 13 Stage IA-IIA CTCL
patients, with 5 screen failures. Seven have completed at least 3 cycles. Among these, 6 (86 %) had
>75% reduction in modified severity-weighted assessment tool (mSWAT) score, with 5 complete
responses (CR), 1 partial response and 1 stable disease. No Grade (Gr) III adverse effects (AE) were
observed, 6 patients had Gr II AE and 6 patients had Gr I AE. No Gr II AE occurred when the BCNU
dose was reduced to 20 mg. The most common Gr II AE were rash/desquamation and skin pain in
6 patients. Biopsy of skin reactions revealed interface dermatitis in 5 patients with prominent
macrophage infiltration and activation (TNF and iNOS). Interestingly, 4 patients with skin AE had a
CR, suggesting that the mechanism underlying the reactivity may be linked to clinical response.
Overall, the 71 % CR rate of this study exceeds the 19 % CR rate previously observed with a sin-
gle dose of O6BG, which appears to confirm the hypothesis that a more durable inhibition of AGT
inhibition potentiated topical BCNU efficacy (as well as toxicity).
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Developing a novel personalized interactive health care education system (MyPACE) for acne
patients
AS Wang, J Wu, N Foolad and AW Armstrong Dermatology, University of California, Davis,
Sacramento, CA
Ensuring medication adherence for acne treatment has been a constant challenge. Poor adherence
may stem from patients’ lack of knowledge or misunderstanding of their skin condition or prescribed
treatment regimen. To promote patient comprehension about acne and increase medication adher-
ence, we developed a novel Internet-based personalized interactive health care education system
(MyPACE: My Personalized Application for health Care Education). The MyPACE system utilizes
the concept of “spaced education” in which regular exposure to educational content aims to enhance
comprehension and retention. Specifically, patients receive weekly emails with a link to five on-
line multiple-choice acne-related questions for a total of 12 weeks. All questions are followed imme-
diately by explanations with a focus on (1) clinical features and epidemiology, (2) pathogenesis, (3)
treatment, (4) adverse effects of medications, and (5) treatment adherence. The Internet-based design
of this system makes it easily accessible from home or a mobile device. A randomized controlled
study evaluating the efficacy of the MyPACE system in improving medication adherence as well as
clinical outcomes and quality of life is currently underway. Overall, the MyPACE system exempli-
fies how advances in communication technology coupled with “spaced education” methods can
enhance patient education and empower patients to actively participate in their health care deci-
sions.
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The safety and efficacy of tongue piercing in people quadriplegia for use with assistive neuro-
technologies
JS Holbrook,1 JS Minocha,1 D Rowles,1,2 B Nardone,1 V Godinez-Puig,1 DP West,1 E Roth,1,2
M Ghovanloo3 and AE Laumann1 1 Northwestern University, Chicago, IL, 2 Rehabilitation
Institute of Chicago, Chicago, IL and 3 Georgia Institute of Technology, Atlanta, GA
The Tongue Drive System (TDS) is an assistive neuro-technology that uses a magnet attached to the
tongue to allow individuals with severe neurological disorders to interact wirelessly with the envi-
ronment, enabling the performance of tasks such as operating a computer or driving a wheelchair.
The safety and efficacy of tongue piercing and the use of a magnet-containing barbell are being
investigated as a means of attaching a magnet to the tongue. The tongues of 7 able-bodied adults
and 5 adults with quadriplegia were pierced in a medical setting and a standard barbell was inserted.
This was exchanged for a magnet-containing barbell after four weeks. Objective and subjective
measures were recorded immediately following and for 12 weeks up to the completion of the TDS
testing sessions when a comprehensive questionnaire was administered. There were no severe adverse
events and the procedure was well tolerated by both groups. Adherence to aftercare instructions
and intra-oral cleanliness was better among people with quadriplegia than among the able-bodied
group, and at the barbell exchange less plaque was seen on the jewelry of those with quadriplegia.
In conclusion, using careful exclusion criteria, no excess risk was found associated with tongue
piercing and the wearing of tongue jewelry in people with quadriplegia compared with able-bod-
ied people.
512
Two photon polymerization-micromolding of microscale barbs for medical applications
A Nasir,1 RD Boehm,2 B Chen,2 SD Gittard,2 BC Chichkov,2 N Monteiro-Riveire2 and R Narayan2
1 Dermatology, UNC Chapel Hill, Chapel Hill, NC and 2 Joint Department of Biomedical
Engineering,, UNC Chapel Hill, Chapel Hill, NC
Tissue barbs are small-scale structures may be used for sutureless joining of tissues. In this study,
several types of tissue barbs were fabricated using two photon polymerization micromolding, includ-
ing two-pronged tissue barbs, eightpronged tissue barbs, ten-pronged tissue barbs, and sixteen-
pronged tissue barbs. Tissue barb penetration of porcine tissue was observed using confocal laser
scanning microscopy. Medical tape-tissue barb constructs were created by applying tissue barbs in
a parallel arrangement to Transpore™ medical tape. These results suggest that two-photon poly-
merization- micromolding is an indirect rapid prototyping approach that may be used for high-
throughput replication of tissue barbs and other microstructured solid wound sealants.
510
Autoantibody profiling alludes to a protective role for discoid lesions in human lupus
BF Chong,1 L Tseng,1 T Lee,1 R Vasquez,1 Q Li,2 S Zhang,3 D Karp,2 N Olsen4 and C Mohan2 1
Dermatology, University of Texas Southwestern, Dallas, TX, 2 Internal Medicine, University of
Texas Southwestern, Dallas, TX, 3 Clinical Sciences, University of Texas Southwestern, Dallas,
TX and 4 Internal Medicine, Penn State University, Hershey, PA
Systemic lupus (SLE) patients with discoid lupus (DLE) have been reported to have milder disease.
To test this observation, we used autoantigen arrays to compare autoantibody profiles of SLE sub-
jects without DLE (DLE-SLE+), SLE subjects with DLE (DLE+SLE+), DLE subjects without SLE (DLE+SLE-
), and healthy subjects. We incubated sera from age-, and gender-matched DLE-SLE+ (N=9), DLE+SLE+
(N=10), DLE+SLE- (N=11), and healthy subjects (N=11) on sandwich arrays containing 98 autoanti-
gens. We validated differentially expressed autoantibodies using ELISAs and Luminex® assays in
DLE-SLE+ (N=18), DLE+SLE+ (N=17), DLE+SLE- (N=23), and healthy subjects (N=22). Autoantigen
arrays showed 15 IgG autoantibodies, with ten against nuclear antigens, and four IgM autoanti-
bodies that were differentially expressed (q-value<0.05). Anti-double-stranded DNA (dsDNA), -sin-
gle-stranded DNA (ssDNA), -double-stranded RNA (dsRNA), -histone H2A and H2B, and -SS-A (52
kDa) IgG were highest in DLE-SLE+ subjects, followed by DLE+SLE+, DLE+SLE-, and healthy sub-
jects (p<0.05). ELISAs and Luminex® assays measuring anti-dsDNA, -ssDNA, and -SS-A (52 kDa)
IgG showed similar trends (p<0.05). Healthy and DLE+SLE- subjects expressed higher anti-alpha
beta crystallin, -lipopolysaccharide, -heat shock cognate 70, and -desmoglein-3 IgM than DLE+SLE+
and DLE-SLE+ subjects. IgG:IgM autoantibody ratios against mostly nuclear antigens peaked in DLE-
SLE+ subjects versus the other groups, particularly DLE+SLE+ subjects (p<0.05). In conclusion, lower
IgG autoantibodies against nuclear antigens in DLE+SLE+ versus DLE-SLE+ subjects imply that dis-
coid lesions lessen disease severity. Higher IgM autoantibodies against selected antigens in healthy
and DLE+SLE- subjects may impair disease spread. Whether the autoantibody differences are merely
disease markers or actively reshape disease warrants further mechanistic studies.
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Oral plethysmography: A novel method to clinically assess tongue swelling
JS Minocha,1 JS Holbrook,1 J Kim,2 E Sutton,3 J Bruce,3 DR West,1 M Ghovanloo2 and
AE Laumann1 1 Dermatology, Northwestern University Feinberg School of Medicine, Chicago,
IL, 2 GT Bionics Lab, Georgia Institute of Technology School of Electrical and Computer
Engineering, Atlanta, GA and 3 Spinal Cord Injury Lab, Shepherd Center, Atlanta, GA
Tongue piercing is being investigated for use with an assistive-neuro technology. Tongue swelling
is a common complication of piercing. To get an objective assessment of tongue swelling a novel
non-invasive method was used to measure change in oral cavity capacity (OCC). 24 subjects, 12
healthy able-bodied adults and 12 adults with quadriplegia, participated in the study. Each subject
maximally filled the mouth with water; then expelled it into a graduated beaker. The average of 5
measurements was taken at baseline prior to piercing, 24, 48, and 72 hours and 4-5 weeks post-
piercing. Width/thickness, photographs, and visual inspection of tongues were recorded at the same
time points for the subjects with quadriplegia and only at baseline prior to piercing, 72 hours, and
4-5 weeks post-piercing for the able-bodied subjects. One able-bodied subject withdrew after 48
hours. OCC was decreased from baseline during the first 72 hours after piercing in all subjects.
Changes in OCC negatively correlated with measured tongue thickness and observed swelling.
This method may prove useful in the clinical evaluation of tongue swelling.
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ARG0542-01: A new cosmetic functional ingredient to improve redness and blemishes
E Perez,1,2 JR Fernandez,1,2 K Rouzard,2 M Voronkov,1,2 M Christensen,3 X Feng,2 M Stock,2,1
JB Stock,2 JS Gordon1,2 and B Shroot1,2 1 Argyle Therapeutics, Monmouth Junction, NJ, 2
Signum Biosciences, Monmouth Junction, NJ and 3 Springhouse Skin Research, Merion, PA
Propionibacterium acnes (P. acnes) is a major contributing factor to the inflammatory component
of acne. The interaction of P. acnes with keratinocytes leads to an innate immune response via acti-
vation of toll-like receptors (TLR2, TLR4) resulting in the production and secretion of pro-inflam-
matory mediators. Here we report the effect of ARG0542-01, an isoprenylcysteine (IPC) small mol-
ecule on the modulation of inflammatory signaling pathways, P. acnes viability, human tolerance
and an instrumental assessment of ARG0542-01 topical gel in acne prone subjects. Human ker-
atinocytes were exposed in culture to P. acnes and peptidoglycan to induce IL-8 production and P.
acnes were cultured anaerobically to determine minimal inhibitory concentration (MIC) and min-
imal bactericidal concentration (MBC) values. Thirty acne prone subjects were randomized in a
double-blind instrumental clinical assessment of 3% ARG0542-01 gel or vehicle for 6 weeks bid.
ARG0542-01 in vitro demonstrated an IC50 of 0.3 and 3 μM against peptidoglycan and P. acnes
induced IL-8 production respectively and a bactericidal effect of ~5 μg/ml against P. acnes. A 3%
ARG0542-01 gel was well tolerated with no signs of stinging, redness or itching in acne prone sub-
jects. Furthermore, improvements were observed in the ARG0542-01 group, including inflamma-
tory lesions, micro-comedone counts and sebum levels (Sebutape). In addition ARG0542-01 gel
significantly reduced by ~1.0 log10 colony reduction P. acnes colony forming units (facial scrub).
ARG0542-01 represents a novel cosmetic functional ingredient that provides a safe dual modulat-
ing benefit to individuals with acne prone skin by reducing P. acnes counts and reducing inflam-
mation.
516
Oral supplementation with a pine bark extract containing nutritional supplement: Molecu-
lar evidence for beneficial effects on skin elasticity and hydration
S Grether-Beck,1 A Marini,1 T Jaenicke,1 M Weber,1 C Burki,2 P Formann,1 H Brenden,1
F Schönlau2 and J Krutmann1 1 IUF – Leibniz Research Institute for Environmental Medicine,
Duesseldorf, Germany and 2 Horphag Research, Cointrin/Geneva, Switzerland
In recent years there is increasing interest in the use of nutritional supplements to benefit human
skin. Molecular evidence substantiating such effects, however, is scarce. In the present study we
have investigated whether nutritional supplementation of women with the standardized pine bark
extract Pycnogenol® will improve skin physiological parameters and if yes, whether this is associ-
ated with concomitant changes in the expression of corresponding molecular markers of their skin.
For this purpose twenty healthy postmenopausal women were supplemented with Pycnogenol®
for 12 weeks. Before, during and after supplementation, their skin condition was assessed by employ-
ing (i) non-invasive, bio-physical methods including corneometry, cutometry, visioscan and ultra-
sound analyses and (ii) by taking biopsies and subsequent PCR analysis for expression of genes
related to extracellular matrix homeostasis. Pycnogenol® supplementation was well tolerated in all
volunteers. Pycnogenol® significantly improved hydration and elasticity of skin. These effects were
most pronounced in women presenting with dry skin conditions prior to start of supplementation.
The skin physiological improvement was accompanied by a significant increase in the mRNA expres-
sion of hyaluronic acid synthase-1 (HAS-1), an enzyme critically involved in the synthesis of hyaluronic
acid, and a noticeable increased of gene expression involved in collagen de novo synthesis. This
study provides skin-physiological and for the first time molecular evidence that Pycnogenol® sup-
plementation benefits human skin by increasing skin hydration and skin elasticity. These effects are
most likely due to an increased synthesis of extracellular matrix molecules such as hyaluronic acid
and possibly collagen. Pycnogenol® supplementation may thus be useful to counteract the clini-
cal signs of skin aging.
517
High-sensitivity c-reactive protein response to adalimumab in hidradenitis suppurativa patients
CC Zouboulis,1 DA Adams,2 Y Gu3 and OM Goldblum3 1 Dessau Medical Center, Dessau,
Germany, 2 Penn State Hershey Medical Center, Hershey, PA and 3 Abbott Laboratories,
Abbott Park, IL
Determine the impact of adalimumab (ADA) treatment on high-sensitivity C-reactive protein (hs-
CRP) in patients (pts) with moderate to severe hidradenitis suppurativa (HS). Initial 16 wk double-
blind, placebo (pbo)-controlled portion of a Phase II, 52 week (wk) trial. Pts with moderate to
severe HS (HS-Physician’s Global Assessment [HS-PGA] ≥moderate) were randomized 1:1:1 to ADA
40 mg weekly (ew) (after 160 mg at Wk 0 and 80 mg at Wk 2), ADA 40 mg every other wk (eow)
(after 80 mg at Wk 0), or pbo. The primary efficacy variable was the proportion of pts achieving Clin-
ical Response (HS-PGA score of clear, minimal, or mild, with at least a two grade improvement at
Wk 16 relative to Baseline). A post-hoc analysis reports mean change in hs-CRP concentration
from Baseline to Wk 16 by treatment group and by the proportion of pts achieving at least a two
grade improvement at Wk 16 relative to Baseline (Responders and Non-Responders defined based
on their response accordingly). Pts with missing PGA data at Wk 16 were imputed as Non-Respon-
ders. 154 pts were enrolled: 51 pbo/52 eow/51 ew. At Wk 16, the proportion of pts achieving Clin-
ical Response was 3.9%/9.6%/17.6% for pbo/eow/ew groups (n=36/40/35; P=.025, ew vs. pbo);
mean hs-CRP concentrations at Baseline were 13.8/17.8/22.2 mg/L; and mean change in hs-CRP
from Baseline to Wk 16 was 4.4/-3.1/-7.9 mg/L (P=<.05, ew vs. pbo). Responders and Non-Respon-
ders (defined in post-hoc analysis) for pbo/eow/ew pts had a mean change from Baseline to Wk 16
in hs-CRP of -1.7/-2.3/-2.0 mg/L (n=2/9/7) and 4.8/-3.3/-9.5 mg/L (n=33/31/25; P<.05, ew vs. pbo),
respectively. Weekly ADA therapy was effective in reducing hs-CRP concentrations in moderate to
severe HS pts. Despite stringent response criteria, both Responders and Non-Responders showed
reductions in hs-CRP levels from Baseline.
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Imatinib mesylate for the treatment of sclerotic skin chronic graft-versus-host disease
K Baird, S Booher, L Comis, G Joe, SM Steinberg, WD Figg, SD Spencer, N Takebe, S Pavletic and
EW Cowen National Institutes of Health, Bethesda, MD
The mechanisms responsible for sclerotic-type chronic GVHD of the skin (ScGVHD) are unclear;
however, platelet-derived growth factor (PDGF) and transforming growth factor-β (TGFβ) have
been implicated. Imatinib mesylate is a tyrosine kinase inhibitor with activity against both PDGFR
and TGFβ and an established safety profile for the treatment chronic myelogenous leukemia. How-
ever, its safety and efficacy in ScGVHD is unknown. 20 patients were enrolled in a Phase II study
of imatinib mesylate for the treatment of ScGVHD. Eligible patients had ScGVHD limiting range-
of-motion (ROM) in at least 1 joint by >25%. Initially, patients were given 400mg (pediatric
260mg/m2) with dose reduction allowed for toxicity (cohort 1). Due to a high incidence of adverse
effects, the study was amended to 100mg with escalation to 200mg daily at 1 month (cohort 2). The
6 month primary endpoint was percent ROM change at 1-3 target joints: partial response (PR) =
>25% gain; progressive disease (PD) = >25% loss, or >1 steroid pulse per 3-month period; stable
disease (SD) = all other. Secondary endpoints included toxicity, skin score, patient-reported qual-
ity of life and functional measures, serum drug concentrations (cohort 2), and other cGVHD organ
response. At 6 months, two patients had PD, 5 PR, 7 SD, and 6 were non-evaluable. 11/14 (78.6%)
evaluable patients had ROM improvement (mean gain 31%). No significant improvement was seen
in other cGVHD manifestations. Adverse events included hypophosphatemia, GI upset, fatigue,
muscle cramping, tinnitus and pulmonary edema. Mean steady-state serum drug concentration
(1157ng/mL) in cohort 2 (200mg) was within the PDGFR inhibitory range. This data suggests that
low-dose imatinib therapy has efficacy for ScGVHD; however, tolerability is a significant issue when
utilized in patients with ScGVHD.
519
Stimulation of hair growth in humans by cell-secreted proteins
GK Naughton,1 C Ziering,2 N Sadick,3 D Perez-Meza,4 M Hubka,1 D Ehrlich1 and J Mansbridge1
1 Histogen, San Diego, CA, 2 Ziering Medical, Los Angeles, CA, 3 Sadick Dermatology, New
York, NY and 4 Permanent Hair Solutions, Maitland, FL
We have evaluated a bioengineered human cell-derived formulation, termed Hair Stimulating Com-
plex (HSC), on the effects of hair growth activity in male pattern baldness and female diffuse hair
loss. HSC is produced by cells grown on beads in hypoxic bioreactors and contains cytokines includ-
ing KGF,VEGF,follistatin and noggin. Follistatin and noggin antagonize activin and BMPs which
maintain the quiescent state of hair follicle stem cell proliferation. We hypothesized that injection
of this medium may increase the supply of progenitor and transit amplifying keratinocytes to the
hair shaft, leading to an increase in the thickness of the hairs and a reversal of the miniaturization
process. Three clinical studies have been performed. The pilot study was a double-blind, random-
ized, placebo-controlled trial involving 26 men with androgenetic alopecia. At baseline one area
of the scalp received (4) 0.1cc intradermal injections (injs) of HSC and the parallel site received
identical injs of placebo. HSC showed an excellent safety profile and a statistically significant increase
in hair shaft thickness (p<0.05) at 3 months and hair density at 3 months (p <0.03) and 1 year (p<0.03)
as assessed by Trichoscan image analysis. Analysis of the distribution of hair density at 1 year showed
that the effect was no longer localized to 2-3mm around the injection site, as was the case at 12
weeks. Increased terminal hairs were seen in the entire region within the 4 injection sites support-
ing the hypothesis that HSC stimulated resting and miniaturizing follicles to increase terminal hair
growth. A Phase I/II 55 patient trial with an identical protocol but with 8 injs of HSC and control at
baseline and a repeat dose at week 6 has completed enrollment. A 10 patient non-controlled study
for men and women with hair loss is being conducted, with patients receiving 20 injs of HSC at
baseline and week 6. The efficacy results seen with HSC represent a novel regenerative medicine
approach in hair growth treatment.
520
Stratum Corneum hydration and barrier function in podoconiosis patients
JS Ferguson, G Davey, P Matts, P Mortimer, W Enbiale and C Fuller Lymphoedema and Vascular
medicine, St Georges University London, London, United Kingdom
Podoconiosis (non-filarial elephantiasis) is a common cause of lymphedema in barefoot workers in
highland Ethiopia. Untreated, patients are at risk of frequent episodes of acute cellulitis, their great-
est risk of mortality. Understanding the pathogenesis of cellulitis is key to identifying treatments.
Skin changes are a dominant feature of podoconiosis. We hypothesise that an increase in stratum
corneum (SC) stiffening induced by low water content leads to mechanical fragility and consequent
cracking and splitting of the skin barrier in the feet of these patients. To investigate SC hydration and
barrier function in podoconiosis patients compared to controls. 54 patients and 21 controls were
recruited from a Podoconiosis Clinic, a community meeting and hospital outpatients in Debre
Markos, Ethiopia. Demographics, foot and leg circumferences were recorded. Trans-Epidermal Water
Loss (TEWL) and hydration measurements were taken at 3 points on both lower limbs. As expected,
foot circumference in podoconiosis patients was increased significantly (p<0.05) relative to the con-
trol group. TEWL values were similar, although there was a trend towards higher values on the feet
in podoconiosis patients relative to controls. Striking differences were seen, however, in SC hydra-
tion where values were significantly reduced (p<0.05) on all leg sites of podoconiosis patients rel-
ative to the control group. SC hydration values for the thigh, calf and foot in podoconiosis patients
were significantly different (p<0.05) and decreased towards the foot. Furthermore, a negative cor-
relation (r=0.38; p<0.05) was observed between foot/leg circumference ratio and foot SC hydra-
tion. While TEWL values were similar, SC hydration values were significantly reduced on the legs
of podoconiosis patients relative to controls, particularly on the feet. This significantly supports our
hypothesis. This breach in SC protection is critical as it may allow ingress of bacteria and soil par-
ticles, believed to be central to the pathogenesis of cellulitis and podoconiosis.
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Peptides involved in neurogenic inflammation induced by histamine and capsaicin-A non inva-
sive study using Raman spectroscopy
R Valdes-Rodriguez,1 FJ Gonzalez,2 C Castillo-Martinez,1 B Moncada,1 D Hernández-Blanco1
and G Yosipovitch3 1 Department of Dermatology, Hospital Central “Dr. Ignacio Morones
Prieto”, San Luis Potosi, Mexico, 2 Coordinación para la Innovación y la Aplicación de la
Ciencia y la Tecnología., Universidad Autónoma de San Luis Potosí., San Luis Potosi, Mexico
and 3 Department of Dermatology, Wake Forest University School of Medicine, Winston-
Salem, NC
Neurogenic inflammation (NI) develops as a result of activation of sensory nerves which secrete
neuropeptides such as CGRP, Substance P, Tryptase, Cathepsin S, Histamine. Capsaicin and Hista-
mine cause NI and the sensation of a burning pain and itch. Assessment of peptides involved in NI
in humans has been rarely investigated and requires an invasive approach. The aim of the current
study is to assess the peptides involved in neurogenic inflammation and their correlation to symp-
toms of burn and itch non-invasively. Raman spectroscopy is a non-invasive and non-destructive
optical technique that gives information on the molecular composition of the analyzed sample. Fif-
teen healthy subjects were evaluated using Capsaicin 0.1% cream, a 1% solution of histamine dis-
solved in 2% methylcellulose gel and a moisturizing cream with no active ingredient. The 3 sub-
stances were applied topically to the volar parts of right and left forearms. Raman Spectra of the
skin were taken using a Raman Systems R-3000 Raman spectrometer with a 785nm laser and an 8
cm^-1 spectral resolution, measurements were performed before and at 2, 4, 6, 12, 18, 24 and 30
minutes post application for each substance. High purity CGRP, Substance P, Tryptase, Cathepsine
S and Histamine were also analyzed using Raman spectroscopy and their spectra was used to esti-
mate the amount of these substances present on the skin. The burn and itch sensations for each sub-
ject were assessed during several time points and correlated to the peptides levels estimated non-
invasively through Raman spectroscopy. The results show that Raman spectroscopy was able to
detect the peptide levels and can be utilized to assess neurogenic inflammation non-invasively.
523
Use of expert modeling to assess the best compound for transdermal development
V Schmith,1 J Lenn,2 H Hofland,2 P Turnbull1 and H Groenendaal3 1 GlaxoSmithKline, Research
Triangle Park, NC, 2 Stiefel, Research Triangle Park, NC and 3 EpiX Analytics, Boulder, CO
The skin penetration model is a valuable tool to study the rate/depth of topical drug delivery into
human skin. Since in vitro skin flux studies are small and receiving fluid is not fully physiologic,
mean skin flux alone may not accurately predict the amount of compound reaching the systemic
circulation. Uncertainty and other factors (e.g., dermis) may also contribute to the likelihood of ade-
quate systemic exposure. We used expert modeling, and combined many sources of data, includ-
ing their uncertainty, to assess the best compound for transdermal development. Six experts sepa-
rately rated (scale 0-1, sum=1) the value of data (e.g., in vitro skin flux, amount in dermis, skin
irritancy, potency) for a transdermal product and characterized the minimal change considered
important for each assessment. Using standard methodology, six compounds were assessed using
the skin penetration model. The average flux of Compounds A and B was 2-fold higher compared
to four other compounds, suggesting that Compound A or B may be optimal compounds for trans-
dermal delivery. Monte Carlo simulations (n=10,000) were conducted, assuming the mean =/- SD
of observed data from each component (e.g., in vitro skin flux, skin irritancy). For each simulation,
the rating and the magnitude of change from one of six experts was randomly chosen and a utility
index (describing each compound relative to the mean of six compounds) was calculated, with
positive attributes (e.g., skin flux) added and negative attributes (e.g., irritancy) subtracted. Results
showed that the utility index was similar for all compounds, with no compound showing a clear
advantage. Based on the mean effect alone, Compounds A & B look intriguing. However, when
including the uncertainty and quantifying the positive and negative attributes of a compound using
expert modeling, there was not an apparent advantage with Compound A or B. Thus, better deci-
sions can be made about progression of a candidate when uncertainty and expert opinions are quan-
tified.
525
Treatment of pemphigus vulgaris(PV) patients with infliximab and prednisone is associated
with decreased autoantibodies and an increase in immature B cells
R Hall,1 J Fairley,2 D Woodley3 and V Werth4 1 Duke University, Durham, NC, 2 University of
Iowa, Iowa City, IA, 3 USC, Los Angeles, CA and 4 Univ. of Pennslyvania, Philadelphia, PA
A randomized, double-blind placebo controlled trial of infliximab(INFX) with prednisone vs. pred-
nisone alone was conducted in PV patients to assess safety, efficacy and pathogenesis. PV patients
who had ongoing disease activity while on prednisone (> 20 mg/d) were maintained on prednisone
(> 20 mg/d) and randomized to either INFX (5 mg/kg weeks 0, 2, 6, 14) or placebo. 10 subjects
were randomized to each group; 12 males, 8 females, median age 52.5 yrs. Response status was
assessed at 18 and 26 weeks. Responders achieved a prednisone dose < 25% of the starting dose
or < 10 mg/d and had no new blisters within the prior 4 weeks. IgG anti-DSG1 and DSG3 anti-
bodies and B cell phenotypes were assessed. There were no safety signals; 27 of 165 AEs were ≥
Grade 2 (8 INFX, 19 placebo); 4 AEs lead to therapy discontinuation (2 INFX, 2 placebo). 6 SAEs
occurred in 3 subjects (1 INFX; 2 placebo). 1 subject (placebo) died of pulmonary embolism on
day 17. At week 18, 1 subject in each group had responded. By week 26, 3 subjects had responded
(3 INFX, 0 placebo; p =0 .21). IgG antibodies to DSG3 were detected in 18 subjects (median 500
u/ml) and to DSG1 in 15 (median 84.0 u/ml). Analysis of per protocol subjects (6 INFX, 7 placebo)
showed that with INFX IgG anti DSG1 and DSG3 dropped steeply from day 0 to week 18 then
remained stable through week 26; in the placebo arm, levels remained stable throughout the study
(weeks 22, 26; p<.05 for DSG1; GLM F test). B cell phenotypes were assessed using multi-color
FACS in 10 subjects (5 INFX, 5 placebo). In the INFX arm, the % CD38++/IgD+ B cells increased
steadily from day 0 through week 26 but remained relatively stable in the placebo arm (week 26;
p= 0.09; GLM F test). This study suggests that treatment with INFX and prednisone may be benefi-
cial for some PV patients refractory to conventional therapy and that INFX may be associated with
a decrease in anti-DSG1 and DSG3 antibodies.
524
High probability that plasma calcipotriene concentrations are nonquantifiable in pediatric
subjects
V Schmith,2 MR Wyres,1 J Lenn,1 E Kang2 and M Mills1 1 Stiefel, Research Triangle Park, NC and
2 GlaxoSmithKline, Research Triangle Park, NC
Plasma calcipotriene concentrations (Cp) were nonquantifiable (<10 pg/mL) in all but one sample
from 16 adults with plaque psoriasis receiving topical administration of calcipotriene foam (0.005%)
on 10% of the body surface area (BSA) BID x 2 weeks. A simulation study was conducted to eval-
uate the probability that Cp would be quantifiable in 2 to 16 years old subjects after topically admin-
istered calcipotriene foam, given that skin penetration and systemic absorption may differ signifi-
cantly between adults and pediatric patients. The Farahmand & Maibach equation was used as a
conservative estimate of Cmax of calcipotriene given topically (ie., transdermal Cmax >> topical
Cmax) in pediatric subjects 2-16 years old. Parameters included estimates of slopes and intercepts,
uncertainty in these estimates, and model misspecification error (CV=70%). BSA was calculated
based on the Center for Disease Control height and weight growth charts. Simulations (n=10,000)
were conducted for 4 scenarios: psoriasis covering 5-10% of BSA (base case), 25-35% of BSA
(maximum use), and 35-50% and 50-75% of BSA (two worst case scenarios). Comparing differences
in results from 5-10% to 50-75% represent a 7-10 fold change in skin penetration between adults
and pediatrics, while comparing difference in results between 25-35% to 50-75% represents a 2-3
fold change in skin penetration between adults and pediatrics. Simulations showed that the most
likely Cmax is <0.25 pg/mL for all but the 50-75% scenario which was <4 pg/mL (LLQ 10 pg/mL).
The probability of achieving quantifiable Cp is <1% for scenarios in patients with psoriasis with 5-
10%, 25-35%, or 35-50% of BSA, and <4.1% when assuming psoriasis with 50-75% of BSA in pedi-
atric patients 2 to 16 years of age. Thus, even if skin penetration is 10-fold higher in pediatrics than
adults, simulations suggest a >95% probability that Cp would be unquantifiable in pediatric patients
with psoriasis receiving calcipotriene foam.
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Low skin thinning potential of pimecrolimus cream versus triamcinolone cream on other-
wise normal forehead target area skin in adults with a history of atopic dermatitis
HI Katz,1 C Boeck,1 T Lin,2 K Abrams3 and JT Olin2 1 University of Minnesota, Minneapolis, MN,
2 Valeant Pharmaceuticals North America LLC, Bridgewater, NJ and 3 Novartis
Pharmaceuticals Corporation, East Hanover, NJ
Topical corticosteroids are the standard of care for atopic dermatitis (AD) flares despite a risk of skin
atrophy with prolonged use. Pimecrolimus cream 1% (PIM) is a non-steroid AD treatment approved
in patients ≥2 years of age. This randomized, double-blind, within-patient comparison study assessed
skin thickness (assessed by ultrasound [US]) and skin thinning weekly in adults with a history of
AD. 22 subjects were treated with PIM and triamcinolone acetonide cream 0.1% (TA), each applied
BID to separate, uninvolved, contralateral target sites on otherwise normal forehead skin. The pri-
mary endpoint was the percent change in skin thickness from Baseline to Visit 10 (Week 8). A skin
thickness decrease of ≥15% at a site required discontinuation of that treatment. Secondary end-
points included percent of sites demonstrating skin thinning (decrease of ≥15% in skin thickness);
clinical “naked eye” observations of telangiectasia, shiny appearance, transparency, depressed skin
surface, dermatoglyphic loss, striae, and/or hypopigmentation; and stereomicroscopic (8X magni-
fication) presence of covert subpapillary superficial vascular plexus (pre-atrophy) and/or telangiec-
tasia. At the study endpoint, significantly more TA-treated than PIM-treated sites (45% [10/22] vs
5% [1/22]) displayed skin thinning (p=0.007, McNemar’s test). A between treatment difference in
skin thickness (p=0.008, Wilcoxon signed rank test) was seen as early as Week 3, at which time the
median percent changes were -7.4% with TA and -1.9% with PIM. A significant treatment differ-
ence persisted for the remainder of the study. No overt signs of skin thinning were observed. Covert
pre-atrophy was reported in 2 subjects (1 PIM, 1 TA). No other treatment discontinuations due to
adverse events were reported. These results confirm previous findings that PIM overall has a low
skin thinning potential.
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Double-blind placebo-controlled clinical study of a nutritional supplement containing Lac-
tobacillus rhamnosus T12 for enhancement in dermatological conditions characterized by
sebum production alteration
G Giuliani,1 B Marzani,1 A Benedusi,1 B Tenconi2 and A Sparavigna2 1 R&D, Giuliani SpA, Milan,
Italy and 2 DermIng Srl, Istituto di Ricerche Cliniche e Bioingegneria, Monza, Italy
The effectiveness of Lactobacillus rhamnosus T12 dietary supplement was evaluated in a random-
ized double-blind placebo-controlled clinical trial in subjects with impaired production of sebum.
In the study were enrolled 44 subjects randomly assigned to active product or placebo intake, once
a day for 2 months. The parameters were measured by dermatological (visual score of the main
clinical signs of acne: comedones, papules, pustules, erythema, scaling, seborrhea, microcysts)
and instrumental (evaluation of sebum, hydration, pH, evaporation, surface microrelief, sebum-
regularizing properties and antioxidant comedolytic through the minimal erythema dose) evalua-
tions at basal condition, after 1 and 2 months of treatments. The results obtained show that Lacto-
bacillus rhamnosus T12 intake determined, after 1 month, a significant reduction in sebum, into
skin desquamation and a significant increase in hydration. The improvement of the active product
are attributable to its regularization of sebum property, resulting in skin pH normalization, and the
comedolytic effect after 2 months. In conclusion, the data obtained support the use of the L. rham-
nosus T12 containing supplement in the treatment of impure skin and in the most important skin
diseases characterized by sebum production alteration such as seborrheic dermatitis and acne.
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Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell
lymphoma patients
H Zhong, L Shiue, Y Mekhail, M Goswami, M Duvic and X Ni The University of Texas MD
Anderson Cancer Center, Houston, TX
Cutaneous T-cell lymphomas (CTCL) are characterized by skin-homing malignant T helper (Th)
cells with a Th2 phenotype which leads to the imbalance of Th1/Th2 cytokines and the immune sup-
pression in CTCL. Extracorporeal photopheresis (ECP) is an effective therapy for erythrodermic CTCL,
but its mechanisms of action are not fully understood. In this prospective translational study, we
evaluated Th1/Th2/Th17/Treg cytokines in late stage CTCL patients who had blood involvement
and the effect of ECP on these cytokines. The serum samples were collected from 21 patients at pre-
ECP (n=21) and post-ECP at Day 2 (n=16), 1 month (n=19), 3 months (n=16), and 6 months (n=17).
The Human Cytokines MultiAnalyte ELISArray was used to assess the levels of Th1-related cytokines
(IL-2, IL-12 and IFN-γ), Th2-related cytokines (IL-4, IL-5, and IL-13), Th17 related cytokines (IL-6
and IL-17A), and Treg related cytokines (IL-2, IL-10 and TGF-β1). At baseline, patients had lower
levels of IL-12 and IFN-γ, and higher levels of IL-4, IL-5, and IL-13 than normal donors (ND). TGF-
β1 was significantly increased (an average in CTCL: 52.6 ng/ml vs. ND 5.7 ng/ml, student t test,
p<0.05). Over 6 months of ECP treatment, IL-12 and IFN-γ increased gradually, especially in ECP
responders (n=10) with an average 2.2-fold increase of IL-12 and 1.6-fold increase of IFN-γ. In
addition, responders had slightly higher levels of IL-12 and IFN-γ at baseline than non-responders
but lower IL-5 and IL-13. Compared to non-responder, responders had slightly lower levels of IL-
17A, IL-10 and TGF-β1 at baseline; they trended to increase after ECP. Interestingly, responders in
this study had lower IL-2 (17.3 pg/ml) at baseline compared to non-responders (226.6 pg/ml, p<0.05)
and remained low during ECP treatment. Our results confirm that CTCL patients have imbalanced
Th1/Th2 cytokines and also dysregulated Th17/Treg cytokines and rebalance of these cytokines by
ECP may contribute to the clinical efficacy of ECP in CTCL patients.
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Extent of variability in doses of foam products following typical application directions
EG Kang,1,2 EK Hussey,3 M Mills,3 M Wyres3 and VD Schmith1 1 GlaxoSmithKline, Research
Triangle Park, NC, 2 UNC Eshelman School of Pharmacy, Chapel Hill, NC and 3 Stiefel
Laboratories, Research Triangle Park, NC
The amount of topical foam products and the total number of canisters needed for each patient are
difficult to quantify as standard directions are given as “apply a thin layer to affected areas” or as
“apply a golf-ball size of foam to scalp”. Interpretation of a thin layer or golf ball size, body surface
area (BSA), and the %BSA affected by disease contribute to the dose variability. Risk analysis meth-
ods allow quantification of the uncertainty and variability, so that a range of expected doses (and
resulting number of canisters) can be provided to clinicians as references. Data from the use of three
foam products (calcipotriene 0.005%, clobetasol propionate 0.05% and betamethasone valerate
0.05%) was examined, along with demographic data, in an attempt to quantify the dose of each
product administered in adult patients. ModelRisk software (Vose Software) was used to conduct
10,000 simulations. First, the amount of dose per unit area was determined based on several meth-
ods (e.g., directions in protocol, industry standard of 1 g/3% BSA for an adult, amount/cm2 used in
bioavailability studies). The weight of patients in the Phase II/III studies was used for this assess-
ment. Then, the amount per unit area affected was multiplied by the BSA of the general population
of males and females and the expected size of the treated area. Variability and uncertainty were
added to each step. The range of doses to treat 10% of the BSA was 1.5 to 7 g for calcipotriene foam
and 1 to 12 g for clobetasol foam. The range of doses of betamethasone foam needed to treat the
scalp ranged from 1.5 to 4.5 g in adult patients. The average dose is well represented by the indus-
try standard of 1 g/3% BSA, but actual doses need to be considered in practice given the large vari-
ability in BSA and interpretation of dosing instructions. Accounting for this variability and quanti-
fying the range of doses can help in planning of experimental studies and in clinical care.
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Barrier enhancement for eczema prevention- the BEEP feasibility study
EL Simpson,1 JR Chalmers,2 JM Hanifin,2 ME French,3 T Lubianski,3 A Samrao,3 Y Chen,3 Z Chen3
and HC Williams2 1 Dermatology, Oregon Health & Science University, Portland, OR, 2 Centre
of Evidence Based Dermatology, University of Nottingham, Nottingham, United Kingdom and
3 Oregon Clinical and Translational Research Center, Oregon Health & Science University,
Portland, OR
The prevalence of atopic dermatitis (AD) is over 20% in many parts of the world. To date, strategies
to prevent AD have primarily involved allergen avoidance. Given recent data implicating the skin
barrier in AD pathogenesis, we hypothesized that optimizing skin barrier function from birth with
daily full body emollient therapy may prevent the onset of AD. The main objective of the current
study was to evaluate the feasibility of this approach. We undertook a multi-center, randomized,
controlled study evaluating emollient therapy from birth to 6 months of age in neonates from atopic
families. Four centers in the UK and one in the US participated. The majority (>65%) of potential
participants identified pre- or post-delivery agreed to participate. Parents randomized to the emol-
lient intervention group (n=64) could choose between an ointment, cream, or sunflower oil with
most choosing cream (67.2%). Parent randomized to the control group (n=60) were asked to refrain
from using routine emollients on their newborn. The emollient group reported using the emollient
5-7 days per week in 88.4% percent of the follow-up visits. There were no differences in adverse
events between groups. While the study was not powered for efficacy, out of the children who under-
went skin examination (n=108), 41.5% of the children in the control group developed clinical evi-
dence of eczema, compared to 21.8% of the children in the emollient group (p=0.028). Skin bar-
rier function was also assessed in a subset of subjects (n=32). While no significant differences were
found between groups, a trend toward improved barrier function was seen in the emollient group.
Emollient therapy from birth appears to be a safe and feasible approach for AD prevention. Pre-
liminary results are encouraging and suggest a preventive effect of this approach. Larger controlled
studies are warranted.
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The missing chromophores in the analysis of human skin color: Comparison of tristimulus col-
orimetric measurements and chromophore analysis from diffuse reflectance spectroscopy
I Seo, PR Bargo, G Payonk, Y Liu and N Kollias Models and Methods, Johnson and Johnson
Consumer Products Company, Skillman, NJ
Instrumental colorimetry has often been used as an objective measure of perceived skin color by
human eye to document and score physiological responses of the skin. The color of human skin is
primarily dominated by the presence of chromophores. CIE color space values (L*, a* and b*) are
the most commonly used parameters to correlate visually perceived color attribute with L* for pig-
ment, a* for erythema, and b* for sallowness of the skin. In this study, we examined the corre-
spondence of L*a*b* color scale to the amount of skin chromophores (oxy-, deoxyhemoglobin and
melanin) calculated from diffuse reflectance spectroscopy (DRS) and compared with a digital imag-
ing under different lighting modes. Three hundred healthy human subjects of ages from 20 to 70
years old and skin types I-VI were recruited for the study. DRS and colorimetry measurements were
taken from the left and right cheeks, and on the right upper inner arm. The lightness of skin (L*) was
shown to correlate to the melanin content calculated from 630—700 nm range of DRS measure-
ments for darker skin. For subjects with medium-to-light complexion, the relation of L* versus melanin
content was interfered by the presence of hemoglobin and melanin measured at the blue part spec-
trum. There was a strong correlation of L* and a* for sun-protected sites while the amount of hemo-
globin calculated from DRS measurements showed little variations for all skin types. A new method
for quantifying melanin at the blue part spectrum of DRS measurement revealed a correlation of b*
scale that is for the sallowness of the skin. This study demonstrates that the addition of missing chro-
mophores to the model is required to bring the analysis of the contributor to skin color in line with
clinical observations.
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Gadolinium in the skin of those with nephrogenic systemic fibrosis (NSF) compared to those
without NSF- A 5 cohort analysis
B Nardone,1 KE Holzem,1 D Mai,1 P Gerami,1 K MacRenaris,2 DP West1 and AE Laumann1 1
Dermatology, Northwestern University, Chicago, IL and 2 Chemistry of Life Processing
Institute, Northwestern University, Chicago, IL
Nephrogenic systemic fibrosis (NSF) has been associated with exposure to gadolinium-based con-
trast agents in people with severe renal dysfunction. The aim of this study is to determine if gadolin-
ium (Gd) is present in involved skin samples of individuals with NSF compares to similar skin sam-
ples taken from persons without NSF. A total of 24 tissue samples were evaluated: (a) 2 subjects
with NSF; (b) 4 subjects who had received Gd in the context of chronic kidney disease (CKD) but
did not develop NSF; (c) 2 subjects who had neither received Gd nor had compromised renal func-
tion; (d) 9 subjects with normal renal function who had received Gd; (e) 7 neonatal foreskin sam-
ples as a control group. Gd content was determined using inductively coupled plasma mass spec-
trometry of acid digested de-paraffinized tissue samples allowing for reliable quantitative trace
element analysis down to 10 pg of Gd per mL of solution. Gd content in samples from NSF patients
was higher in NSF samples compared to the control group (ANOVA p<0.05;p=0.04). No signifi-
cant difference was found when comparing all other cohorts with the control group. Of note, the
Gd content in the NSF skin revealed a trend toward a significant increase compared to subjects
who had received Gd but had no history of kidney disease (ANOVA p=0.057). Our results support
the association between Gd and NSF, as it is present in the involved tissues of patients with the con-
dition. These findings also support an association between NSF and renal failure. Moreover, our
results suggest that other factors may contribute to Gd deposition in the tissue of those with NSF as
there was no significant difference in skin Gd levels between subjects without NSF who had CKD
and were exposed to Gd and the control group.
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Safety and efficacy of AN2728 and AN2898 ointments in a phase 2a bilateral study of mild-
to-moderate atopic dermatitis
LT Zane, T Gogoleva, FA Heerinckx and JA Jermano Anacor Pharmaceuticals, Palo Alto, CA
To determine the safety and efficacy of AN2728 Ointment, 2% and AN2898 Ointment, 1%, admin-
istered twice daily (BID), compared to Ointment vehicle in the treatment of mild-to-moderate atopic
dermatitis. Multicenter, phase 2a, randomized, double-blind, vehicle-controlled, 6-week, bilateral
comparison study. 46 adult patients with mild-to-moderate atopic dermatitis were randomized
(1:1) to receive either AN2728 Ointment, 2% vs. Ointment vehicle or AN2898 Ointment, 1% vs.
Ointment vehicle applied BID to two similar target lesions on the trunk or extremities for 6 weeks.
Lesion severity was measured using a static scale for Atopic Dermatitis Severity Index (ADSI; 0 to
15), which represents the sum of the scores of five characteristics, erythema, excoriation, exuda-
tion, lichenification, and pruritus, each scored on a scale of 0 to 3. Compared with those treated
with vehicle, lesions treated with AN2728 Ointment, 2% as well as those treated with AN2898 Oint-
ment, 1% achieved greater improvement in ADSI in a significantly higher proportion of patients
after 4 weeks (co-primary endpoints). Further, AN2728 Ointment, 2% and AN2898 Ointment, 1%
each outperformed vehicle ointment in mean improvement of lesion severity from baseline as well
as in the proportion of lesions achieving total or partial clearance (ADSI ≤ 2) at the same time point.
No serious adverse events were observed in the trial. Treatment appeared safe and well-tolerated.
AN2728 and AN2898 are boron-based phosphodiesterase-4 inhibitors, well-suited for the topical
treatment of inflammatory skin disorders. AN2728 has previously demonstrated safety and efficacy
in multiple Phase 1 and 2 trials for mild-to-moderate psoriasis. Overall, these Phase 2a results show
that AN2728 Ointment, 2% and AN2898 Ointment, 1% are each effective in reducing the severity
and signs of atopic dermatitis lesions and appear safe and well-tolerated. Additional studies in
younger age groups are planned.
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Immunologic rationale and therapeutic efficacy of a novel single-dose radiation therapy
approach for Merkel cell carcinoma metastatic lesions
J Iyer,1 K Nagase,1 O Afanasiev,1 A Seo,1 K Parvathaneni,1 K Paulson,1 U Parvathaneni2 and
P Nghiem1,2 1 University of Washington, Seattle, WA and 2 Fred Hutchinson Cancer Research
Center, Seattle, WA
Merkel cell carcinoma (MCC) often progresses to distant metastases that are typically treated with
chemotherapy or radiation therapy (RT) delivered in multiple fractions. Survival after MCC is asso-
ciated with immune status both systemically and within the tumor microenvironment. Increasing
evidence suggests RT may shift immunity toward a favorable TH1 response. Mouse data show that
single dose RT is more effective in augmenting immunity than fractionated RT, as subsequent radi-
ation fractions suppress the function of T cells recruited to the tumor. We thus explored the use of
single dose RT in MCC. 14 MCC tumors from 6 patients were treated with a single 8 Gy dose (median
follow up of treated lesions: 103 days; range 4–392 days). Of the 6 patients, 3 had tumors at diffi-
cult visceral sites, 2 had multiple locoregional recurrences and 1 had nodal MCC. Among the 5
patients who received no other subsequent treatment (2 of which had previously failed chemother-
apy), 3 had complete responses (CR; 7 total treated lesions, including 5 visceral lesions in a chemore-
fractory patient) and 2 had a partial response (PR; 6 lesions). No patient had disease progression
within the irradiated fields. Importantly, no side effects were noted in any patients following this
regimen. MCC is commonly treated with fractionated RT requiring 10-30 therapy visits that are dif-
ficult for patients, particularly in the palliative setting. 8 Gy RT has an extremely favorable side effect
profile with excellent early responses, although longer follow up will be critical. This approach is
particularly promising for MCC involving visceral sites, for which the morbidity of traditional frac-
tionated therapy is prohibitive. Serologic, lymphocyte functional studies and careful tracking of non-
irradiated lesions over time will examine the role of augmented immunity in response to single-dose
8 Gy therapy.
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Replumping effect on lips, and anti aging effects by specifically targeting ECM components.
In vivo study
G Oberto, Y Guerif-Ferreira, A Berghi, K Cucumel and N Domloge Global Skin Research Center,
ASI ISP Vincience, Sophia Antipolis, France
The extracellular matrix represents an essential element in the architecture and functioning of the
skin. Indeed, skin matrix is a privileged place for cellular exchanges, and it maintains cutaneous
integrity and communication, but declines and deteriorates with age. Hence, we were interested
in evaluating, in vivo, the effects of a new compound, IV10.005, that targets extracellular matrix
proteins and showed to counteracts the increase of aging marker expression in vitro. The in vivo
anti-aging properties of IV10.005 at 1% were determined by a double-blind study versus placebo.
A first study to demonstrate the replumping effect on lips was conducted on 16 volunteers sepa-
rated in two groups. After three applications a day during 14 days, we only found a significant
increase of the lip hydration, an increase of the lip volume, and lips seemed smoother (observable
effects are both seen by volunteers and the expert). In the second clinical study, we were interested
in the anti-aging effect of the IV10.005. Twelve volunteers applied both the inducer-containing and
placebo creams twice a day on the face during two months. The microrelief (silicone replicas of the
crow’s feet) was analyzed with Quantirides® software. After 56 days of treatment, application of
the IV10.005 revealed a significant decreases of average and total wrinkle lengths, and average wrin-
kle depth. Furthermore, the anti-wrinkle effect of IV10.005 was visible in the crow’s feet area and
perceived by 70% of volunteers. In conclusion, these results confirms that enhancing skin ECM leads
to perceivable replumping and anti-aging effects and is of interest for the anti aging approach.
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DNA telomere protection exhibits anti aging effects. In vivo study
K Cucumel, Y Guerif-Ferreira, A Berghi, G Oberto, S Darly and N Domloge Global Skin Research
Center, ASI ISP Vincience, Sophia Antipolis, France
Skin aging is a complex biological process that includes intrinsic aging (effects of time) and extrin-
sic aging (environmental effects such as solar irradiations). Intrinsic aging is also commanded by
genetic material and progressive telomere shortening. Hence, we were interested in telomere pro-
tection and in understanding the cross talks between proteins associated with telomere; in order to
provide lights on some of telomere-associated aging. In the purpose to study genome stability and
telomere integrity, we designed a new compound (IV10.008) that targets Shelterin components and
double-stranded DNA breaks. In vitro studies revealed IV10.008 effect on maintaining Sheltering
component after stress exposure. Hence, we examined its in vivo effects with a clinical test com-
paring a cream containing IV10.008 compound at 1% versus a placebo cream. A two-month dou-
ble-blind study was conducted on 18 volunteers during the summer. They applied the creams twice
a day on the face, and once on the arms. After eight weeks of application, the IV10.008 compound
helped limiting significantly signs of aging, as it helped increasing hydration and improving qual-
ity of the skin on the area of the arm. These results were confirmed by a microrelief study on the
area of the face: silicone replicas of the crow’s feet were analyzed with Quantirides® software. This
study confirms that the skin is highly aggressed during summer time, as shown by wrinkle param-
eters increase. However, IV10.008 helped limiting and decreasing these aging signs significantly.
In conclusion, protecting Sheltering components seems essential for cellular longevity and func-
tioning and its protection is important for anti aging goals.
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Dermatopontin plays an essential role in skin aging. In vivo study
Y Guerif-Ferreira,1 G Oberto,1 L Mur,1 C Plaza,1 A Berghi,1 F Portolan,1 G Menon,2 K Cucumel,1
J Botto1 and N Domloge1 1 Global Skin Research Center, ASI ISP Vincience, Sophia Antipolis,
France and 2 ASI Corporate Research Center, Ahsland Specialty Ingredients, Wayne, NJ
Skin aging is a complex process of which the most striking response is the loss of elasticity leading
to the appearance of wrinkles and skin slackening. Recent studies have suggested the role of der-
matopontin in improving skin firmness and elasticity. Indeed, this protein forms a complex with
other molecules, which are responsible for fibrillogenesis and adhesion of fibroblasts to dermal
fibers. Therefore, the dermatopontin is considered to play important roles in cell-matrix interactions.
We were interested in evaluating further the role of extracellular matrix, and especially dermato-
pontin, in dermal aging; and the effect of this molecule on dermal regeneration and skin elasticity.
For this, we developed a new compound, IV09021, that showed, in vitro, an enhancing effect on
major dermal component. The anti-aging effects of IV09021 at 1% were determined, in vivo, by a
double-blind study versus placebo. The clinical study was realized on 12 volunteers during four
weeks. They applied IV09021 -containing and placebo creams twice a day on the neckline. We
used the Reviscometer® in order to evaluate the skin elasticity. After four weeks of application, we
found that the compound helped to significantly improve skin elasticity. Interestingly, Visioscan®
images revealed that skin microreliefs were less marked, less deep; and led to triangular and hexag-
onal skin image as expected in young skin. These in vivo results confirm dermatopontin remarkable
role in improving skin anisotropy an important feature of aging.
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Hematopoietic and mesenchymal cell transplantation after myeloablative and non-myeloab-
lative conditioning for recessive dystrophic and junctional epidermolysis bullosa (RDEB,
JEB)
J Tolar,1 JA McGrath,2 DR Keene,3 K Hook,4 MJ Osborn,1 MJ Riddle,1 S Kavand,4 M Hordinsky,4
D Woodley,5 M Chen,5 A Hovnanian,6 K Tamai,7 BR Blazar1 and JE Wagner1 1 Blood and Marrow
Transplant, University of Minnesota, Minneapolis, MN, 2 Kings College London, London,
United Kingdom, 3 Shriners Hospital, Portland, OR, 4 Dermatology, University of Minnesota,
Minneapolis, MN, 5 Dermatology, University of Southern California, Los Angeles, CA, 6
INSERM, Paris, France and 7 Stem Cell Science, Osaka University, Osaka, Japan
We found previously that hematopoietic cell transplantation (HCT) in RDEB ameliorated mucocu-
taneous manifestations, but 2 of 7 patients died. To improve outcomes, we next chose to combine
HCT with infusion of tissue-reparative and immune-modulatory mesenchymal stromal/stem cells
(MSCs), and compare clinical benefit after myeloablative versus potentially safer non-myeloabla-
tive conditioning. We also hypothesized that JEB could respond favorably to allogeneic transplan-
tation. Twelve individuals with EB (RDEB = 9; JEB-Herlitz = 3) received allogeneic hematopoietic
cells and MSCs. 7 RDEB and 2 JEB patients received myeloablative conditioning. Of these, 4 patients
died of either acute progression of disease or complications of HCT. The remaining 5 individuals (1
JEB and 4 RDEB) are alive more than 1 year after HCT. In addition, 2 RDEB and 1 JEB patients received
non-myeloablative conditioning and are alive between 43 and 229 days after HCT. Of the 6 evalu-
able patients, all have improved wound healing and reduction in blister formation. Within this, 3
RDEB have increased expression of collagen VII, and 1 JEB has increased expression of laminin-
332 at the dermal-epidermal junction, with 2-30% of their skin cells derived from the HCT donor.
MSC infusions were well tolerated and transient engraftment of donor MSCs was observed in 2
patients. In sum, allogeneic HCT/MSC transplantation can result in biochemical correction and clin-
ical improvement in both JEB and RDEB, and non-myeloablative conditioning may potentially medi-
ate at least short-term clinical benefits similar to those observed after myeloablative conditioning.
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Clinical characteristics correlates with impaired barrier in filaggrin gene related Korean atopic
dermatitis patients
S Seo, M Park, M Jeong, J Kim, I Kim and K Li Department of Dermatology, Chung Ang
University College of Medicine, Seoul, Republic of Korea
Filaggrin is a key protein involved in skin barrier function. Mutations in the gene encoding filaggrin
(FLG) have been identified as the cause of ichthyosis vulgaris and have been shown to be major
predisposing factors for atopic dermatitis (AD). Recently, lots of researches about the expression of
filaggrin actively progressed, the fact that FLG mutations have been reported as an important pre-
disposing factor for AD and secondary atopic phenotypes such as atopic asthma, suggests that the
skin barrier defect is a primary key event leading to allergic sensitization and development of AD
and related allergic phenotypes. The purpose of this study was to investigate the clinical character-
istics of the AD patients with FLG mutations, and make the differences in two AD patient groups
divided by presence or absence of FLG mutations. After identifying the FLG mutations of AD patients
by full sequencing and snapshot methods, clinical characteristics aware from questionnaires were
correlated and analyzed. In results, Earlier Age onset of AD (P=0.047), present tendency to respi-
ratory atopy (P=0.029), severe AD clinical characteristics (Higher EASI score) (P=0.018), decrease
in skin hydration (P=0.04) were showed in FLG-related AD. Our data conclusively demonstrate
that identification of FLG mutations is an indicator of a poor prognosis in AD, and predisposing fac-
tor that starts in early infancy and persists into adulthood.
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Topical mousse in the treatment of acne vulgaris: A randomized double-blind placebo-con-
trolled clinical trial
G Giuliani,1 B Marzani,1 A Benedusi,1 A Bonfigli2 and L Rigano2 1 R&D, Giuliani SpA, Milan,
Italy and 2 ISPE, Milan, Italy
Acne, one of the most frequent dermatologic manifestations affecting pilosebaceous units, affects
a large number of people. Topical therapy is the standard treatment and the use of specific cosmetic
products is an usual practice. Considering the main pathogenic mechanisms of acne and the role
of UV a new product (mousse) containing sunscreen has been developed. Its effectiveness has
been evaluated in the treatment of acne lesions in a double-blind randomized placebo-controlled
trial. 20 male and female subjects affected by mild and moderate acne was included in the study.
The subjects applied the two test products (active and placebo) for a month twice daily, one prod-
uct per half of the face. The instrumental and clinical evaluations were performed before treatment,
after 2 weeks and at the end of treatments. The results showed a statistically significant decrease in
the number of papules since after two weeks of active product treatment, while no changes were
observed for placebo. After 4 weeks treatment statistically significant decrease was reported for the
main acneic manifestations, erythema while an improved in skin smoothness. The results obtained
demonstrate the efficacy of the new product in the treatment in mild and moderate acne.
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Cross-sectional evaluation of biological markers of cardiovascular disease risk in children and
adolescents with psoriasis
WL Tom, PW Lee and LF Eichenfield Division of Dermatology (Pediatrics and Medicine), UC
San Diego/Rady Children’s Hospital, San Diego, CA
Medical advances have demonstrated wide-ranging systemic effects from long-term, uncontrolled
inflammation, shifting psoriasis from a primarily skin and joint condition to a systemic disorder. An
increased risk for metabolic syndrome and cardiovascular disease has been well-demonstrated in
adults with psoriasis, but the potential risks for affected children are only beginning to be defined.
This cross-sectional, single-center study assessed the levels of markers of cardiovascular disease
risk in 50 children and adolescents with psoriasis and 50 age- and sex-matched healthy controls.
Subjects were 13.3 +/- 4.1 years of age (mean +/- SD). Psoriasis subjects had Psoriasis Area Sever-
ity Index (PASI) scores of 5.6 +/- 5.2, with 56% having mild, 32% moderate, and 12% severe dis-
ease. Body mass index (BMI) was 24.4 +/- 7.1, with 16% being overweight and 32% obese. Con-
trols had BMI of 22.1 +/- 4.1, with 22% being overweight and 10% obese. The two groups did not
differ significantly in their measured values of fasting glucose, cholesterol, triglycerides, low and
high density lipoproteins, or liver function tests. However, a greater number of psoriatic than con-
trol subjects had AST or ALT abnormalities, hypercholesterolemia, increased blood triglycerides,
and increased fasting insulin levels. Five of the psoriasis patients had evidence of systemic inflam-
mation, with elevated C-reactive protein, while no controls had abnormal levels. In our study, pso-
riasis in children and adolescents was associated with increased frequency of obesity and abnor-
malities in markers of metabolic syndrome and cardiovascular risk.
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Punch incision with removal of cyst contents leaves a smaller scar yet has a similar rate of
recurrence compared to elliptical excision of truncal epidermal inclusion cysts
JT Cheeley, LK DeLong, SC Chen, MM Pennie, SP Kini and S Setzer Dermatology, Emory
University, Atlanta, GA
We sought to longitudinally compare elliptical excision (EE) and punch incision (PI) with removal
of cyst contents of epidermal inclusion cysts (EICs) on the basis of scar length, recurrence, and
quality of life (QOL). 40 subjects with 1-3 cm truncal EICs were randomized to either PI or EE. Mul-
tiple cysts in a subject were treated with the method to which the subject was randomized. Patients
followed up with a 2 week post-operative visit and with a telephone survey administered by a blinded
observer at 1, 4, 10, and 16 months, asking about recurrence and QOL as measured by the Skindex-
16 . After univariate analyses, two multivariate regression models were performed. The primary
outcome was EIC recurrence and the other was a change in Skindex-16 scores from baseline to 16
months. Baseline characteristics of subjects and cysts were not significantly different between the
PI (n=19) and EE (n=21) groups. The average procedure duration and rate of complications and recur-
rence (16% vs. 10%) was not significantly different between PI vs. EE. Average scar length was sig-
nificantly smaller in PI vs. EE immediately post-op (10.2 mm vs. 19.6mm, p<0.001) and at 2 week
follow-up (10.7 mm vs. 17.7mm, p=0.004). The average change in Skindex scores from baseline to
16 month follow up was not statistically significantly different between PI vs. EE (21.0 vs. 17.2). By
multivariate logistic regression, treatment type, cyst diameter, cyst location, and procedure time
were not statistically significant predictors of cyst recurrence. By multivariate linear regression, none
of the same variables were statistically significant predictors of change in Skindex-16 scores while
controlling for cyst number. In conclusion, PI is an effective means to extirpate truncal epidermal
inclusion cysts <3 cm in diameter while significantly reducing scar length. Rates of post-operative
complications and recurrence, as well as skin-specific QOL improvement measures, are similar
between PI and EE.
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Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in
psoriasis
E Botti, M Talamonti, G Spallone, M Galluzzo, M Bavetta, M Teoli, V Pinetti and A Costanzo
Dermatology, University od Rome “Tor Vergata”, Rome, Italy
Genetic and environmental factors are involved in determining the appearance of psoriasis, many
studies have shown the high prevalence of the HLA-Cw6 allele in patients affected by moderate to
severe psoriasis suggesting a role for this allele in the immune system dysfunction associated with
psoriasis. Recently, the deletion of LCE3B and LCE3C genes (LCE3C_LCE3B-del), members of the
late cornified envelope (LCE) gene cluster, was significantly associated with risk of psoriasis, sug-
gesting that compromised skin barrier function may have a role in psoriasis susceptibility. Objec-
tive of the present study was to determine whether the presence of HLA-Cw6 allele or LCE3B_3C
gene deletion might influence response to the IL-12/23 blocking antibody ustekinumab. To this
aim, we have performed HLA-Cw6 haplotyping and assessed the presence of LCE3B and LCE3C
deletion in 40 patients affected by moderate to severe plaque psoriasis and treated with ustekinumab
for at least 52 weeks. We have evaluated if the response to ustekinumab was associated to the pres-
ence of the HLA-Cw0602 allele. Our data indicate a faster initial clinical response to ustekinumab
in Cw6 positive patients. At week 4 PASI 50 was reached by 80% of Cw6 positive patients and in
50% of Cw6 negative patients (p<0,01), while no difference was observed at week 12 and 24. When
considering the presence of LCE3B_C deletion, we haven’t observed any significant variation in
response to ustekinumab. Similar results were obtained when considering PASI75. Also we have
studied the a mutual influence between the presence or absence of the HLA-Cw6 allele and the
presence or absence of homozygous or heterozygous deletion of LCE3B and LCE3C finding no sig-
nificant association. Our results suggest that the immune system-related molecule Cw6 rather than
the skin barrier-related molecules LCE3B_C may influence response to the T-cell targeting agent
ustekinumab.
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Preliminary results of a Phase 2 trial evaluating efficacy and safety of vismodegib (GDC-0449)
in operable basal cell carcinoma
KG Gross,1 H Sofen,2 LH Goldberg,3 H Sharata,4 TK Hamilton,5 K Zerivitz,6 H Yue,6 R Firestein6
and I Caro6 1 Skin Surgery Med Grp, San Diego, CA, 2 Derm Research Assoc, Los Angeles,
CA, 3 DermSurgery Assoc, Houston, TX, 4 Madison Skin & Research, Madison, WI, 5 Atlanta
Derm Vein & Research, Atlanta, GA and 6 Genentech, South San Francisco, CA
Basal cell carcinoma (BCC) is the most common malignancy in the US with nodular BCC as the
most frequent clinical subtype (~60%). More than 90% of BCCs may have alterations in the Hedge-
hog (Hh) signaling pathway that cause constitutive signaling and contribute to carcinogenesis. Vis-
modegib is a selective Hh pathway inhibitor that has shown efficacy in advanced BCC. This single-
arm study evaluated the safety and efficacy of vismodegib to produce complete histological clearance
(CCl) in newly diagnosed, nodular, operable BCC. Eligible patients were required to have 1 clini-
cally nodular BCC lesion in the scalp or the “cape” area (chest, shoulders or upper back). After 12
weeks of vismodegib 150 mg orally daily, patients underwent Mohs surgical excision with inde-
pendent pathological review. Twenty-four patients were enrolled: 10 (42%) with a target lesion in
the scalp and 14 (58%) in the “cape” area. Most frequent adverse events (AEs) were: muscle spasms
in 19 patients (79%); dysgeusia 19 (79%); alopecia 8 (33%); fatigue 5 (21%); and nausea 5 (21%).
Most AEs were Grades 1–2; 6 patients (25%) reported Grade 3 AEs. No serious AEs were observed.
One patient was discontinued for ineligibility. Clinical responses were reported in 23 (96%) patients.
Ten patients (42%) achieved CCl as assessed by pathologic examination (95% CI: 23.4%, 63.4%).
In the 10 patients with CCl, clinical assessments showed 5 (21%) CRs, 4 (17%) PRs and 1 (4%) SD.
In the 14 patients (58%) without CCl, there were 5 (21%) CRs and 9 (37%) PRs. In 24 patients with
operable nodular BCC, the pathologic CCl rate was 42% after 12 weeks of vismodegib therapy. Clin-
ical responses were demonstrated in the vast majority of patients. Further study is ongoing to assess
recurrence in similarly treated patients and in patients with longer durations of therapy.
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Thymic stromal lymphopoietin expression in keratinocytes are suppressed by clinical treat-
ments in atopic dermatitis
K Ikeda, S Morizane, Y Aoyama and K Iwatsuki Dermatology, Department of Dermatology,
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
Okayama, Japan
Thymic stromal lymphopoietin (TSLP) is overexpressed in lesional keratinocytes in atopic dermati-
tis (AD). The local increase in TSLP is associated with activation of dendritic cells which trigger the
differentiation of naive CD4+ T cells into proallergic CD4+ Th2 cells. Thus, TSLP is thought to play
an important role in the pathogenesis of AD, but the alteration of TSLP expression after treatment
has not fully been understood. Here we investigated whether TSLP expression in normal human epi-
dermal keratinocytes (NHEKs) could be affected by common clinical treatments including ultravi-
olet (UV) A and B, glucocorticosteroid, and calcineurin inhibitors. Co-stimulation with TNF-alpha
and IL-4 is known to induce TSLP expression in NHEKs. Real-time PCR and ELISA revealed that
treatments of UVA (0.5, 1, 2, and 5 J/cm2) and UVB (0.05, 0.1, 0.2, and 0.5 J/cm2) significantly
suppressed the induction of TSLP expression by co-stimulation with IL-4 (50 ng/ml) and TNF-alpha
(10 ng/ml) in a dose-dependent manner. A synthetic glucocorticosteroid dexamethasone (10-7, 10-
6, and 10-5 M) and a calcineurin inhibitor tacrolimus (10-7, 10-6, and 10-5 M) also suppressed
TSLP expression in NHEKs in a dose-dependent manner. In vivo, treatments with another calcineurin
inhibitor cyclosporine A (3 mg/kg/day) decreased TSLP levels in the sera of AD patients. These mech-
anisms might be associated with the clinical improvements.
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Long-term treatment with ustekinumab does not compromise the immune response to T-cell
dependent or T-cell independent vaccines in patients with moderate-to-severe psoriasis: A
comparison of ustekinumab-treated versus untreated psoriasis patients
C Brodmerkel,1 R Langley,2 K Papp,3 M Bourcier,4 Y Poulin,5 V Ho,6 L Guenther,7 MC Hsu1 and
PO Szapary1 1 Janssen Research & Development, LLC, Spring House, PA, 2 Dalhousie
University, Halifax, NS, Canada, 3 Probity Medical Research, Waterloo, ON, Canada, 4
Dermatology Clinic, Moncton, NB, Canada, 5 Centre Dermatologique du Quebec
Metropolitain, Quebec, QC, Canada, 6 University of British Columbia, Vancouver, BC, Canada
and 7 The Guenther Dermatology Research Centre, London, ON, Canada
The impact of long-term continuous ustekinumab(UST)(anti-IL12/23p40 mAb) treatment on the abil-
ity of patients to mount a response to pneumococcal vaccine (T-cell independent response) and
tetanus toxoid (T-cell dependent response) was assessed. This study was a comparison of patients
treated with UST(≥3yrs), during the long-term extension of the Phase 3 PHOENIX2 trial(n=60), to
“control” patients with moderate-to-severe psoriasis not receiving systemic therapy(n=56). Patients
were vaccinated with 23-valent pneumococcal vaccine and tetanus(Tdap vaccine). Serum samples
were collected pre-vaccination and 4wks post-vaccination and assessed for antibody responses to
the vaccinations. Results showed no differences in the ability of UST-treated patients to mount a
sufficient response to pneumococcal or tetanus toxoid vaccination vs controls. The majority of
patients in both grps achieved >2-fold increase from pre-vaccination to post-vaccination antibody
levels in at least 7 of 14 serotypes of the pneumococcal vaccine (96.6% UST-treated vs. 92.6%
untreated control). 84.7% of patients in the UST-treated group achieved at least a 4-fold increase
in antibody against tetanus toxoid vs 77.8% in the control grp. In an ex vivo T-cell stimulation assay,
no differences were detected in response to anti-CD3/CD28 or tetanus toxoid between patients in
the UST-treated grp and control grp. Results from both in vivo and ex vivo testing demonstrated that
long-term treatment with UST does not compromise the immune response to T-cell dependent or
T-cell independent vaccines in patients with moderate–to-severe psoriasis.
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Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe
palmoplantar psoriasis showed higher doses may be required
S Au,1 AM Goldminz,2 N Kim,1 N Dumont,1 M Michelon,1 E Volf,1 M Hession,1 PF Lizzul,1
I Andrews,1 T Kerensky,1 A Wang,1 S Yaniv1 and AB Gottlieb1 1 Dermatology, Tufts Medical
Center, Boston, MA and 2 Tufts University School of Medicine, Boston, MA
Palmoplantar psoriasis is a variant of psoriasis resistant to many forms of treatment. Twenty subjects
with moderate-to-severe psoriasis of the palms and soles, 50% with pustules at baseline, were treated
with ustekinumab at weeks 0, 4 and 16. All subjects had previously failed topical corticosteroids.
Dosing was 45 mg subcutaneously for subjects weighing <100 kg and 90 mg for subjects weigh-
ing ≥100 kg. The primary endpoint was the percent of subjects achieving clinical clearance at week
16, defined as Palm-Sole Physician’s Global Assessment ≤1. The study received Tufts Medical Cen-
ter IRB approval. After 16 weeks of treatment, 35% (7/20) of subjects achieved clinical clearance.
60% (12/20) improved two or more points on the Palm-Sole Physician’s Global Assessment scale.
67% (6/9) of those receiving the 90 mg ustekinumab dose achieved clinical clearance compared
to 9% (1/11) receiving 45 mg (p=0.02). At 24 weeks, mean values showed 56% improvement in
Dermatology Life Quality Index, and 34% improvement in pain Visual Analogue Scale score (all
p<0.05). Assessment tools for palmoplantar psoriasis are not yet validated. Five subjects withdrew
or were lost to follow-up. This study demonstrates that ustekinumab dosed at 90mg is effective in
controlling signs and symptoms of palmoplantar psoriasis.
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Pimecrolimus cream 1% rapidly reduces the extent and severity of atopic dermatitis in infants
and children, including head-and-neck involvement: post hoc analysis of a 6-month, ran-
domized, vehicle-controlled trial
EC Siegfried1 and JT Olin2 1 Saint Louis University School of Medicine, St Louis, MO and 2
Valeant Pharmaceuticals North America LLC, Bridgewater, NJ
Pimecrolimus cream 1% (PIM) is an alternative to topical corticosteroids (TCS) for the treatment of
atopic dermatitis (AD) in patients 2 years of age or older. In contrast to TCS, PIM can be used on
the face and neck without comparable risk of atrophy or rebound. A previously published 6-month,
randomized, multicenter, double-blind, vehicle-controlled trial including 175 children as young as
3 months of age with mild-to-severe AD demonstrated that the addition of PIM significantly reduced
the incidence of flares and reduced overall TCS exposure. This post hoc analysis assessed overall
and head/neck improvement after the first week of treatment. At Baseline, treatment groups had sim-
ilar total Eczema Area and Severity Index (EASI) scores (mean ± SD: 3.14 ± 2.20 vs 3.33 ± 2.19) and
head/neck sub-scores (19.82 ± 18.90 vs 21.05 ± 21.03). At the end of study Week 1, the mean EASI
change was -1.52 ± 1.85 in the PIM group compared to -0.20 ± 2.00 for the vehicle group (least
squares mean difference [95% CI]: -1.38 [-1.89, -0.87], p<0.001). The mean sub-score changes for
the head/neck were -7.89 ± 14.82 in the PIM group and -3.15 ± 15.40 in the control group (-4.51
[-8.30, -0.72], p=0.020). These data suggest that, in infants and children with mild-to-severe AD,
PIM may be associated with a rapid reduction in the extent and severity of AD, including affected
areas on the head/neck.
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Pilot study of cardiovascular event risk biomarkers in psoriasis patients treated with ustek-
inumab
SE Churton, TS McCormick, KD Cooper and NJ Korman Dermatology, Murdough Family Center
for Psoriasis, University Hospitals Case Medical Center, Cleveland, OH
Psoriasis treatments targeting IL 12/23 p40 may positively or negatively influence cardiovascular
(CV) event risk. We performed a pilot study of 18 psoriasis patients treated with ustekinumab for an
average of 28 weeks (3-4 doses) and evaluated validated biomarkers of CV events capable of detect-
ing change within the time frame of our study. Median age was 49 (range 22-79) and 72% (13/18)
had atherosclerosis defined by positive coronary artery calcium score, presence of carotid plaque
or coronary stent, or carotid intimal medial thickness > 75th percentile. Among 16 patients with
complete myeloperoxidase (MPO) values, MPO decreased by ≥50% in 7/16. Amongst all patients,
the median baseline MPO was 61.6 ng/mL vs. 47.3 ng/mL post treatment. Of note, patients in the
top quartile of MPO values exhibited a reduction from a median of 430 ng/mL at baseline to 52
ng/mL post treatment, suggesting a highly responsive subset. However, MPO increased by ≥50% in
4/16 patients, requiring consideration of an at-risk subset. Among 17 patients with complete high
sensitivity C-reactive protein (hsCRP) values, hsCRP decreased by ≥50% in 4/17 but increased by
≥50% in 2/17 patients. Median hsCRP at baseline was 5.9 mg/L vs. 3.2 mg/L after treatment. Six
patients exhibited coordinate reduction in MPO and hsCRP of ≥25%. Among 14 patients with
complete flow mediated dilation (FMD) values, FMD increased (improved endothelial function) by
≥50% in 6/14 patients but also decreased by ≥50% in 6/14 patients post treatment. No major adverse
cardiovascular events occurred. Our study provides evidence that over an approximately six month
period of ustekinumab treatment for psoriasis patients with a high prevalence of CV disease, there
is significant patient variability in responsiveness of cardiovascular event risk biomarkers. This pilot
study provides data for power analysis to help design a larger study that assesses biomarkers of CV
risk over time in psoriasis patients.
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Efficacy and safety of vismodegib in advanced basal cell carcinoma
A Chang,1 A Sekulic,2 MR Migden,3 A Hauschild,4 K Lewis,5 JD Hainsworth,6 S Yoo,7 L Dirix,8
J Hou,9 H Mackey9 and AE Oro1 1 Stanford University School of Medicine, Stanford, CA, 2
Mayo Clinic, Scottsdale, AZ, 3 MD Anderson Cancer Center, Houston, TX, 4
Universitätsklinikum Schleswig-Holstein,, Kiel, Germany, 5 University of Colorado Cancer
Center, Denver, CA, 6 Sarah Cannon Research Institute, Nashville, TN, 7 Northwestern
University, Evanston, IL, 8 Sint-Augustinus Hospital, Antwerp, Belgium and 9 Genentech, Inc,
South San Francisco, CA
While most basal cell carcinomas (BCCs) are surgically managed, no effective therapy exists for
locally advanced (laBCC) or metastatic BCC (mBCC). A phase 1 study of vismodegib (GDC0449),
a first-in-class small molecule Hh pathway inhibitor demonstrated an investigator assessed 58%
response rate in patients with advanced BCC. This pivotal phase 2 study assessed the safety and effi-
cacy of this drug in advanced BCCs. This multicenter international nonrandomized 2-cohort study
enrolled 104 patients with la BCC (deemed inoperable or for whom surgery would be significantly
disfiguring), and mBCC patients with RECIST-measurable disease. Patients received 150 mg oral
vismodegib daily. The primary endpoint was objective response rate (ORR) by independent review
facility; primary hypotheses tested were that ORR is >20% for laBCC and >10% for mBCC. For
mBCC (n=33), the ORR was 30% (95% CI 16-48%; P=0.0011). For laBCC (n=68), the ORR was
43% (95% CI 31-56%; P<0.0001), including 13 (21%) complete responses. Median duration of
response was 7.6 months in both cohorts. Adverse events (AE) in >30% of patients were muscle
spasms, alopecia, taste disturbance, weight loss and fatigue. Four patients (4%) experienced seri-
ous AE deemed related to vismodegib. This study shows the significant clinical benefit of vismod-
egib in both laBCC and mBCC, and further characterizes the safety profile. These data suggest that
vismodegib is an effective new treatment option for patients with advanced BCC.
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Topical retinol, a precursor to tretinoin, can deliver comparable efficacy to tretinoin in treat-
ment of photoaging 
A Chien,1 N Cheng,1 J Shin,1 M Patel,1 G Hinds,1 J Zang,1 H Suh,1 S Leung,1 B Summerer,1
N Daya,2 S Ghazarian2 and S Kang1 1 Dermatology, Johns Hopkins, Baltimore, MD and 2
Bayview Biostatistics, Epidemiology & Data Management (BEAD) Core, Johns Hopkins,
Baltimore, MD
Retinol (vitamin A=ROL) is sequentially oxidized to tretinoin (retinoic acid=RA), and hence is a
precursor to RA. Topical RA is FDA approved and available by prescription only for management
of photodamage. Topical ROL and several retinyl esters are also available in nonprescription for-
mulations, although their effects on photoaging have been less rigorously studied. We conducted
a double-blinded, single-center, parallel-arm pilot comparison study of ROL 1.0% vs. RA 0.02% in
the treatment of moderate to severe photodamage to assess whether ROL results in similar improve-
ment in photoaging compared to RA. 24 subjects were randomized to undergo 6 months of facial
application of ROL or RA. Assessment of photoaging and tolerability were conducted via physician
assessments and subject questionnaires. Clinical evaluation included Griffith’s photodamage scale,
overall photoaging score, fine wrinkling, coarse wrinkling, and pigmentation. The within subject
test indicates that clinical parameters [0=none, 8=severe] improved over time in both treatment
groups [i.e., for coarse wrinkling of the cheeks: ROL 5.00 to 4.10 and RA 5.17 to 4.82 (p=0.014);
for pigmentation: ROL 4.00 to 3.67 and RA 3.67 to 3.09 (p=0.035)]. However, there were no sta-
tistically significant differences in degree of improvement between the two treatment arms. More-
over, there were also no statistically significant differences in scores on Griffith’s scale, overall pho-
toaging score, fine wrinkling, coarse wrinkling, and pigmentation between the ROL and RA groups.
Although 50 fold greater concentration of ROL was used in comparison to that of RA, there were
also no statistically significant differences in subject and investigator local tolerability assessments.
Our data support that retinol is comparable to tretinoin in improving photaging and is equally well-
tolerated.
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Visualizing the brain processing of the itch-scratch cycle by functional MRI.
AD Papoiu, L Nattkemper, R Coghill and G Yosipovitch Dermatology, Wake Forest School of
Medicine, Winston-Salem, NC
All previous brain imaging studies investigating the brain processing evoked by scratching used an
exogenous intervention mimicking scratching, performed not by the subjects themselves, but deliv-
ered by an investigator using an improvised device. Real scratching is a conscious, voluntary, con-
trolled motor response to itching which is directed to the perceived site of injury and continuously
adjusted by a feedback mechanism. Self-scratching is controlled endogenously by the individual
seeking to relieve itch and features hedonic and algedonic aspects. The intrinsic characteristics of
the active self-scratching motions are inexorably linked in a continuum of feedback loops that assess
receptive inputs and appreciate “the reward”. We aimed to visualize in real-time by brain imaging
(fMRI) the core mechanisms of the itch-scratch cycle: to observe where the decision to scratch is
made, how the motions are adjusted in relation to the induced relief and the pleasurability of scratch-
ing. We also compared the patterns of brain processing evoked by self-scratching vs. passive scratch-
ing (delivered exogenously). We used a robust 3D fMRI technique that was least sensitive to motion
artefacts (3D-GRASE-Propeller). Correlating motor cortex activations with evoked responses in
somatosensory areas represented only one aspect of the phenomena observed. Active scratching
provided a more significant itch relief (as reported in retrospective ratings) and induced a more pro-
nounced deactivation of the anterior cingulate cortex and insula, in comparison with passive scratch-
ing. A significant involvement of the reward system including the ventral tegmentum of the mid-
brain and a potential mechanism for deactivating the Periaqueductal Gray Matter (PAG) as a means
of inhibiting itch processing at the spinal level were observed (suggesting a regulation that operates
in reverse to the mechanism known to suppress pain). These findings emphasize the role of several
central networks processing itch sensation and reveal areas critically involved in itch relief.
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Denosumab is associated with dermatologic toxicity in the FDA-AERS database
V Godinez-Puig,1 B Nardone,1 DP West,1 X Shen,2 DW Raisch,2 JS Holbrook,1 S Belknap,3
N Barahmani1 and BJ Edwards4 1 Department of Dermatology, Northwestern University,
Chicago, IL, 2 Department of Pharmacy Practice & Administrative Sciences, College of
Pharmacy, University of New Mexico, Albuquerque, NM, 3 Department of Medicine,
Northwestern University, Chicago, IL and 4 Bone Health and Osteoporosis Program,
Northwestern University, Chicago, IL
Denosumab (first approved in 2010) is a fully human monoclonal antibody with antiresorptive
actions. Although the FDA lists several cutaneous adverse events (CAE) in the package insert of Pro-
lia®, results of a phase III clinical trial of over 7800 women receiving denosumab for postmenopausal
osteoporosis reported that the only CAE observed were eczema and cellulitis (including erysipelas).
The purpose of this study is to determine the number of reports of CAE associated with denosumab
in the FDA-AERS database using terms related to skin, hair and nail changes, combined with deno-
sumab, from June 1st, 2010 to June 30th, 2011. Proportional reporting ratio (PRR) was calculated.
We identified 33 reports of denosumab-associated CAE, 87.9% (n=29) were females, mean age 70
± 16 years; 63.6% received Prolia® (n=21); the CAE were erysipelas (n=1, 3.0%), hair changes (n=7,
21.2%), stomatitis (n=6, 18.2%), dry skin (n=9, 27.3%) and skin rash (n=10, 30.3%), which included
exfoliative dermatitis (n=4, 40%). Serious CAE occurred in 81.8% of cases (n=27); outcomes included
hospitalization (n=3, 9.1%), life-threatening condition (n=1, 3.0%), death (n=2, 6.1%), other (n=13,
39.4%), and unspecified (n=14, 42.4%). PRR was indicative of signals for skin rash and dry skin
(PRR=2.64, 95% CI=1.33-5.29 and PRR=4.53, 95% CI=2.36-8.72, respectively). Denosumab-asso-
ciated dermatologic toxicity warrants further close monitoring.
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The comorbidities associated with serum vitamin D deficiency in veteran psoriasis and effect
of antioxidant therapy
CN Young,1,2 B Workman,2,1 S Herman,2,1 S Smith,1 C Hatzis1 and LB Savoy1,2 1 Dermatology,
John D Dingell VA Medical Center, Detroit, MI and 2 Dermatology, Wayne State University,
Detroit, MI
The first objective of this study was to assess serum vitamin D level and associations between vita-
min D status and key clinical factors and disease severity in a group of psoriasis patients. The sec-
ond objective was to evaluate comorbidities associated with these patients. The effect of oral sup-
plemental vitamin D3 on serum 25(OH) vitamin D level in psoriasis patients were studied. In addition,
the effect of antioxidants therapy on comorbidities associated with psoriasis was also assessed. The
study was a randomized controlled trial and conducted at Detroit VA Medical center in Detroit
Michigan. Data were drawn from 98 psoriatic patients seen in VA outpatient clinic. Among psori-
asis patients with hypovitaminosis D [25(OH)D < 32 ng/ml], received oral vitamin D3 (cholecal-
ciferol) therapy at a dose of 5000 IU daily respectively for 52 weeks. Among patients with more than
one metabolic syndrome randomly divided into four groups, each group received oral antioxidant
CoQ10, fish oil, NAC or combination of four antioxidant pills (NAC, CoQ, fish oil and VitD) daily
respectively. Blood samples were drawn before, at the week 26 at week 52. Serum measurements
of 25(OH)D, ESR, HbA1c, Lipid Profile, Comprehensive metabolic panel and homocysteine and C-
reactive protein were measured. Blood 25(OH) Vitamin D level from the patients with hypovita-
minosis D increased significantly after six month receiving vitamin D3 supplement at doses of
5000 IU daily. No direct correlation was observed between PASI score improvement and vitamin
D treatment. Serum inflammatory markers CRP, homocysteine, ESR also decreased in all four groups
patients receiving antioxidant pill. But more pronounced improvement seen in the group patients
receiving combination of these four antioxidant pills daily. The significant health benefits of antiox-
idant oral supplements on metabolic syndrome comorbidities associated with psoriasis were elu-
cidated and discussed.
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Local burn injury modulates global cutaneous barrier function
JK Plichta, RP Plichta, RL Gamelli and KA Radek Dept of Surgery, Loyola Health Sciences
Campus, Maywood, IL
Clinical and anecdotal evidence indicate that skin barrier function is globally impaired after burn
injury. Thus, we investigated several key parameters of barrier function in human burn and auto-
graft skin, including antimicrobial peptides (AMPs), proteases (i.e. kallikreins=KLKs), and lipids.
Human burn wound, margin, and autograft skin, or control skin was obtained at surgical excision
or elective surgery, respectively. Previously, we observed robust changes in AMPs, KLKs, and lipid
synthesis enzymes (LSE) in human burn and autograft skin. Here, we further investigated the func-
tional and correlative significance of these data by evaluating 131 samples from 48 patients; mean
age 47 years; mean burn size 7% TBSA. Psoriasin (s100A7) AMP levels were 9-fold greater in burn
wounds vs. controls by ELISA (p<0.05). Furthermore, we found a 50% reduction in protease activ-
ity in autograft skin (p<0.05) by quantitative assay, and a more diffuse distribution of protease activ-
ity in epidermal burn wound and margin vs. controls by immunohistochemistry (IHC). Nile Red
lipid staining yielded a diffuse distribution of lipids throughout the epidermis in burn wound and
margin, in contrast to controls where localization was confined to the more differentiated layers.
Correlative gene expression analyses revealed significant associations between s100A7, catheli-
cidin, hBD1, and hBD4A (p<0.05) AMPs. Notably, KLK5 positively correlated with hBD1, s100A7,
and LSE HMG-CoA reductase (p<0.05), while AMP RNase7 positively correlated with LSEs fatty acid
synthase and serine palmitoyl transferase (p<0.05). Thus, although standard treatment paradigms
suggest that injured skin hinders wound healing and autograft skin retains its functional integrity,
our results contradict this model and establish that burn injury globally alters cutaneous barrier func-
tion via changes in chemical (AMPs) and physical (lipids) components, which likely influence graft
integrity and microbial defense. Understanding how traumatic skin injury systemically alters bar-
rier responses may ultimately improve current therapies and reduce morbidity.
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Inmunohistochemical study on axillary hyperpigmentation and its response to topical treat-
ment with 4% niacinamide vs 0.05% desonide
GN Larraga-P, B Torres-Alvarez, R Valdes-Rodriguez and JP Castanedo-Cazares Dermatology,
Central Hospital Dr. Ignacio Morones Prieto, San Luis Potosi, Mexico
Dark areas of skin in the underarms is a frequent entity in latin american population although the
precise frequency is unknown, it is a cause for dermatologic consultation. It is considered a postin-
flammatory hyperpigmentation when irritation and trauma are the main factors, with an increased
epidermal melanin and dermal melanophages. There is no specific treatment, only lightening agents
such as hydroquinone, azelaic acid, kojic acid, niacinamide and retinoids or steroids due to its
anti-inflammatory effect are used. Our aim was to determine the characteristics of the hyperpig-
mented skin before and after treatment with 4% niacinamide vs 0.05% desonide and determine its
usefulness related to abnormalities such as inflammation, pigmentation and basal membrane integrity.
We included 22 patients with axillary hyperpigmentation (range 18-24 years-old). A colorimeter
was used to evaluate pigmentation and erythema. Biopsies from armpit and perilesional skin were
taken, we used hematoxilin-eosin stain for general histopathology, Masson-Fontana for melanin,
CD68 for monocytes and macrophages, cKit for activated melanocytes, CD1 for Langerhans cells
and collagen IV for basal membrane. We discovered that niacinamide improved the melanin index
compared to desonide, although Masson-Fontana stain showed similar improvement. Activated
melanocytes (cKit) showed a decrease with niacinamide treatment. There were not much differences
in the expression of CD1 or CD68. We found basal membrane disruption in affected skin. Both treat-
ments were equally able to reduce clinical pigmentation. The inflammation in damaged skin was
evident compared to adjacent skin, but the intervention did not reduce it significantly. Basal mem-
brane disruption was a finding that may explain the persistence of hyperpigmentation in this con-
dition.
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Use of brentuximab vedotin for recalcitrant CD30+ cutaneous T cell lymphoma
EE Freeman,1,2 M Tawa,2 AA Dorosario,2 TS Kupper2 and DC Fisher3,2 1 Harvard Dermatology
Residency, Boston, MA, 2 Cutaneous Lymphoma Program, Dana Farber Cancer Center,
Boston, MA and 3 Medical Oncology, Dana Farber Cancer Center, Boston, MA
We report the first case in the literature of the use of brentuximab vedotin in anaplastic large cell
cutaneous T cell lymphoma (CTCL). Brentuximab vedotin is an antibody-drug conjugate, combin-
ing antitubilin agent monomethyl auristatin E with a CD-30 specific monoclonal antibody. It was
recently approved by the FDA in 2011 for: a) Hodgkin lymphoma after failure of autologous stem
cell transplant or failure of at least two chemotherapy regimens and b) systemic anaplastic large
cell lymphoma after failure of a chemotherapy regimen. We report the case of a 51 year old male
with a nineteen year history of primary cutaneous CD-30+ anaplastic large cell CTCL followed at
our institution for the past ten years. He initially had no systemic involvement of the disease, based
on lack of radiographic evidence for lymphadenopathy and negative flow cytometry. Six years ago,
he developed biopsy-proven lymph node involvement. He then progressed to bulky tumor stage
disease despite treatment with eight cycles of CHOP, three cycles of pralatrexate, four cycles of gem-
citabine, two cycles of doxorubicin HCL liposome, two cycles of ifosfamide/carboplatin/etoposide
(ICE), one cycle of pentostatin, and an additional cycle of gemcitibine. Given the recalcitrant nature
of his disease he was started on brentuximab vedotin therapy shortly after its approval by the FDA.
After only one cycle, he noted dramatic interval improvement in tumor burden and had stopped
forming new tumors. He subsequently underwent three more cycles, for a total of four cycles, with
a complete response. He had significant improvement after cycles one and two, but developed
new lesions after the end of cycle three. These responded to a fourth cycle, while awaiting a mye-
loablative stem cell transplant, a procedure from which he is now recovering. We anticipate a grow-
ing role for brentuximab vedotin in CD30+ malignancies involving the skin, including applications
for patients with recalcitrant and extensive disease.
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Control of blood glucose level in type 2 diabetes mellitus patients affects stratum corneum
hydration, which is remarkably improved by a novel moisturizer containing physiologic lipid
granules
N Yoon,1 D Kim,1 N Lee,1 S Park,1 C Chung,2 Y Shin,2 M Lee,2 Y Jeong,3 C Yi3 and E Choi1 1
Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, 2
Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
and 3 AmorePacific R&D Center, Yongin, Republic of Korea
Type 2 diabetes mellitus (DM) induces many skin problems related to chronic impaired skin bar-
rier state. Recently, we reported that a long-standing hyperglycemia decreased stratum corneum(SC)
hydration and delayed skin barrier homeostasis in Otsuka Long-Evans Tokushima Fatty rats, which
correlated with HbA1c levels presenting recent blood glucose control. Also, in this animal model
decreased epidermal lipid synthesis accounted for decreased lamellar body(LB) production. There-
fore, we hypothesized that physiologic lipid granules including ceramide, fatty acids and choles-
terol to mimic LBs with multiple lamellar structures have superior affinity to diabetic skin; better
moisturizing effect. Patients with type 2 DM (n = 43, aged 40-86 years, HbA1c over 7) were recruited
and instructed to apply the moisturizers with or without physiologic lipid granules on each extrem-
ity separately for 4 weeks. Before and after application, SC hydration, basal transepidermal water
loss (TEWL) and barrier recovery rates were measured. Thirty-nine patients completed the study. SC
hydration was significantly decreased in higher HbA1c (over 8.5) group compared to lower group
and increased significantly by moisturizer with physiologic lipid granules in both groups. Basal
TEWL was not different between both groups and not changed by application. Barrier recovery
after tape stripping was significantly faster in moisturizer with physiologic lipid granules, but no dif-
ference between both HbA1c groups. There were no remarkable side effects related with moistur-
izer. In conclusion, SC hydration defining dry skin is much influenced by blood glucose control
(HbA1c level) in type 2 DM patients, which is significantly improved by a novel moisturizer con-
taining physiologic lipid granules.
559
Application of novel imaging tools and analysis methods to quantify and compare efficacy of
various semi-invasive cosmetic treatments
D Qu,1 S Whitehead,1 L Straathof,1 R Fleser,1 G Majmudar,1 GP Seehra1 and G Fisher2 1 Artistry
Center for Skin Health Research, Amway R&D, Ada, MI and 2 University of Michigan Medical
School, Ann Arbor, MI
To date, efficacy differences among semi-invasive cosmetic procedures have not been thoroughly
characterized and quantified. Sensitive and repeatable quantitative measurements of improve-
ments are difficult due to subject variation, clinical operator, instrument, and analysis errors. In this
study, we have systematically controlled these variations by standardizing measurement tech-
niques and developing sophisticated analysis methods. These methods include computerized rou-
tines of image normalization, color correction, facial recognition and facial feature detection and
measurement. We report quantitative results and efficacy comparison on 5 dermal procedures using
3 imaging techniques. The procedures examined were Botox®, dermal filler, fractionated CO2 laser
resurfacing, microdermabrasion and chemical peel, each of which was performed on full face of 5
human volunteers. The instruments used were PRIMOS, 3D skin topography; FACES, facial imag-
ing and analysis; and ultrasound, dermal acoustic density. Wrinkle analysis showed a 32% reduc-
tion in facial wrinkle score after laser treatment, which was statistically more efficacious than
chemical peel (p=0.040). Topographical analysis revealed that skin roughness improvements var-
ied with treatment, with Botox® being significantly more effective than microdermabrasion and
chemical peel (p=0.012 and 0.005, respectively). Dermal density increased 27% after dermal filler
(p=0.008), which was significantly higher than all other treatments. The results indicate that state-
of-the-art instrumentation and image analysis algorithms paired with standardized measurement
techniques have potential to generate efficacy assessments with greater accuracy and sensitivity than
conventional photography or visual inspection by clinician. This approach offers investigators a
better understanding of the relationship between molecular responses and clinical outcomes of cos-
metic treatments.
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Graft-versus-lymphoma effect after non-myeloablative allogeneic transplant induces molec-
ular remission assessed by high-throughput sequencing of T cell receptor in patients with
advanced stage mycosis fungoides (MF) and Sezary syndrome (SS)
WK Weng,1 R Armstrong,1 S Arai,1 K Sutherland,2 RT Hoppe3 and YH Kim2 1 Med/BMT, Stanford
University, Stanford, CA, 2 Derm, Stanford University, Stanford, CA and 3 Rad Onc, Stanford
University, Stanford, CA
MF and its leukemic form, SS, is a non-curable clonal T cell lymphoma primarily arising from the
skin. We have performed non-myeloablative allogeneic transplant in MF/SS patients using total
skin electron beam therapy (TSEBT), total lymphoid irradiation (TLI) and anti-thymocyte globulin
(ATG) preparative regimen in an attempt to provide prolonged disease control. Here, we tested the
ability of high-throughput sequencing of T cell receptor (TCR) to monitor minimal residual disease
(MRD) after allogeneic hematopoietic cell transplant. Genomic DNA was extracted from periph-
eral blood mononuclear cells (PBMC) or skin biopsy samples. The rearranged TCRβ was amplified
using Vβ- and Jβ- specific primers, followed by high-throughput sequencing to generate up to
1,000,000 reads of entire CDR3 lengths. Malignant clone was identified in the blood of all 6 SS
cases tested by a dominant unique CDR3 sequence. At the time of transplant, 3 patients had cir-
culating Sezary cells by standard multi-colored flow cytometry, which was confirmed by TCR sequenc-
ing. The other 3 patients had no detectable Sezary cells by flow cytometry: however, 8.47%, 0.38%
and 0.22% of the TCR sequences were found from malignant clones. The percentage of malignant
clones decreased in all cases immediately after transplant. Three patients eventually achieved molec-
ular remission at day+30, +30 and +270 post-transplant. Experiments using blood samples spiked
with purified Sezary cells demonstrated that TCR sequencing is able to detect Sezary cells as low
as 1 in 50,000 PBMC. This is significantly more sensitive than standard diagnostics. Our findings
demonstrate the utility of high-throughput sequencing of TCRβ in assessing MRD status with utmost
sensitivity and specificity, and for the first time, to show a therapy resulting in molecular remission
in this patient population.
560
Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-
conjugate against CD30, in mycosis fungoides (MF) and Sézary syndrome (SS) demonstrates
clinical responses regardless of CD30 expression levels
S Bashey,1 M Krathen,1 K Sutherland,1 U Sundram,1 B Lingala,1 S Horwitz,2 R Hoppe,1 M Pulitzer,2
R Advani1 and Y Kim1 1 Cutaneous Oncology, Stanford Cancer Center, Stanford, CA and 2
Cutaneous Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Brentuximab vedotin (SGN-35) comprises an anti-CD30 antibody conjugated by a protease-cleav-
able linker to the potent antimicrotubule agent, monomethyl auristatin E, with clinically significant
responses in Hodgkin lymphoma and systemic anaplastic large cell lymphoma, each defined by
uniform expression of CD30+ tumor cells. In MF/SS, CD30 expression levels are lower and more
variable. It is not presently known what level of CD30 expression is necessary to obtain clinical
activity. In this phase II, single-arm study, we explore the efficacy and safety of SGN-35 in MF/SS
with non-detectable to 100% CD30 expression of tissue lymphoid cells by IHC. At the time of this
analysis, 15 patients are evaluable for response: 14 MF, 1 SS, 13 of 15 with stage IIB-IV, 9 with large
cell transformation. Pre-treatment CD30 expression of lymphoid cells showed 7 patients < 10%; 7,
10-50%; 1, >50%. Median age of 64 (20-87); median prior systemic therapies, 4 (1-10). We observed
objective responses in 9 (60%); median skin score (mSWAT) reduction of 55% (0-98%). Clinical
responses were observed in those with all levels of CD30 expression. Median time to response of
7.4 wks (3.0-18.0). To date, neither tissue CD30 expression level nor other clinical/pathological
parameters were predictive of clinical response. Most AE’s in the study were grade 1 or 2 in sever-
ity including fatigue (38%), peripheral neuropathy (38%), rash (19%), and infusion reaction (19%).
2 patients who enrolled with CD30 expressing tumors developed CD30-neg tumors during study.
9 patients continue on therapy. Our exploratory study demonstrates significant clinical activity of
SGN-35 in MF/SS irrespective of tissue CD30 expression levels. Further evaluation is essential to
assess overall clinical benefit of this new antibody-drug-conjugate in this disease population.
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Photosensitivity phenotypes in CLE
K Foering,1,2 A Chang,1,2 E Piette1,2 and V Werth1,2 1 Dermatology, VAMC, Philadelphia, PA and
2 Dermatology, Univ. of Penn., Philadelphia, PA
Photosensitivity (PS) in lupus is ill-defined and often determined by patient report. The purpose of
this study was to characterize clinical photosensitivity phenotypes among a primarily cutaneous
lupus population. The PS questionnaire, developed over a 9-month period, was used to classify
patient responses into 1 of 5 clinical photosensitivity phenotypes based on characteristics, mor-
phology, and time course of sun-induced reactions. Reactions to light were characterized as fol-
lows: specific examples of sun-induced CLE exacerbation (directCLE grp); generalized worsening
of CLE in summer months (genCLE grp); PMLE-like reactions (genSkin grp); pruritus/paresthesias of
sun-exposed skin (genRxn grp); sun-induced systemic symptoms, e.g. headache, fatigue, joint pain
(genSys grp). Of 100 subjects, 83 reported one or more PS phenotypes. The most common PS phe-
notype was directCLE with 47% of subjects citing direct occurrences of sun-induced CLE. 38%
reported genSkin, 36% genRxn, 37% genSys, and 23% genCLE reactions. Overall, 66% of subjects
ascribed to more than one PS phenotype. There was a significant relationship between CLE subtype
and genSys with fewer subjects having DLE and SCLE reporting genSys compared to the other CLE
subtypes, X2=13.0, p<0.05. Subjects having SLE (with CLE) were more likely to report genRxn
(51% vs 23%) and genSys (50% vs 26%) compared with subjects without SLE, p<0.05. Subjects
with genSkin had significantly lower CLASI activity scores compared to subjects with other PS phe-
notypes (6.4±5.4 vs 11.5±11.11, p=0.02). CLASI activity scores did not differ among directCLE, gen-
CLE, genRxn, and genSys phenotypes. While the majority of CLE patients report sun-induced CLE
exacerbation, approximately two-thirds also experience other PS phenotypes such as PMLE-like
eruption, pruritus/paresthesias, and/or systemic symptoms. PS phenotypes are associated with
diagnosis and CLASI activity, but not race. Recognition of various PS phenotypes in CLE will per-
mit improved definitions of clinical photosensitivity and allow for more precise investigation into
the pathophysiology of photosensitivity in lupus.
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Long term outcomes of 1244 patients with mycosis fungoides and Sézary syndrome from 1982
to 2009
R Talpur,1 L Singh,1 S Daulat,1 P Liu,2 S Seyfer,1 T Trynosky,1 W Wei2 and M Duvic1 1
Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX and 2 Biostatics,
University of Texas MD Anderson Cancer Center, Houston, TX
Prognostic variables effecting overall survival (OS) were examined in a prospective cohort of 1244
mycosis fungoides (MF) and Sézary Syndrome (SS) patients at MD Anderson Cancer Centerr: 1982-
2009. Kaplan and Meier estimates were used to determine median overall survival (OS), progres-
sion-free survival (PFS) and disease specific survival (DSS). Cox’s proportional hazards regression
model assessed prognostic factors. Mean age at diagnosis was 55.33 years. Early MF (Stage IA-IIA)
represented 71.9% (895 of 1244) and advanced (Stage IIB-IVB) 28.0% (349 of 1244) patients. Pro-
gression to a higher stage occurred in 147 patients (11.6 %) of whom 112 (12%) were early and 35
(9.7%) advanced. Death from disease occurred in 267/1244 (21.5%) patients. Median OS was 24.44
years, PFS was 16 years, and median DSS was not reached. OS and PFS were significantly better
for early stage patients with patches (T1a/T2a) than for patches/plaques (T1b/T2b). PFS analyzed in
1239 patients found only 336 (27.1%) had disease progression or had died from disease. Risk fac-
tors associated with progression or death were advanced age and stage at diagnosis. Improved out-
come of MF/SS, reflected by median overall survival and PFS for all stages, may result from earlier
diagnosis, new therapies, and aggressive treatment of infections.
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Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with
immunostimulatory adjuvants
O Afanasiev,1 A Chapuis,2 J Iyer,1 K Nagase,1 K Paulson,1 A Seo,1 I Lai,2 I Roberts,2 E Farrar,2
C McClurkan,1 J Marshak,1 L Dong,1 J Hwang,1 D Koelle,1,2 C Yee1,2 and P Nghiem1,2 1 University
of Washington, Seattle, WA and 2 Fred Hutchinson Cancer Research Ctr, Seattle, WA
Merkel cell polyomavirus (MCPyV) oncoprotein (T-antigen) expression is required for tumor growth
in ~80% of Merkel cell carcinomas (MCCs). Viral oncoproteins are an attractive target for adoptive
T-cell therapy. Although most MCCs evade CD8 T cells by down-regulating HLA class-I, we report
that a single dose of either radiotherapy (2-8 Gy) or interferon reverses this HLA-I downregulation.
We used these approaches to reinduce HLA-I prior to virus-specific CD8 T cell infusion. Patient
w447 had a primary MCC on the hip that expressed low levels of HLA-I, high levels of MCPyV onco-
protein, and contained CD8 T cells specific for viral T-antigen. Based on rising antibody titers to
MCPyV T-antigen, he was later found to have a peri-pancreatic metastasis. Blood-derived T cells
with the same MCPyV specificity failed to respond upon peptide challenge and expressed high lev-
els of T cell exhaustion markers PD-1 and Tim-3. To generate therapeutic T cells, autologous lym-
phocytes were cultured with IL-2/IL-7/IL-21, sorted using an HLA-I/peptide tetramer, and expanded.
These polyclonal T cells proliferated and killed appropriate target cells upon challenge. 24 h after
injection of interferon-beta into a tumor nodule, the patient received 23 billion T cells. Four weeks
later, a second T cell infusion was administered 24 h after one dose of 8 Gy radiation to the resid-
ual tumor area. The patient had no adverse effects. After 2 treatments, there was no new distant dis-
ease and all 3 metastatic lesions had markedly responded to treatment (>60% tumor shrinkage by
RECIST criteria). Preliminary data indicate the frequency and functional profile of MCPyV-specific
T cells was increased compared to baseline for >4 weeks after infusion. This study represents a first-
in-man treatment of a solid tumor using T cells targeting an oncogenic viral antigen.
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Stratum corneum hydration and barrier benefits with glycerin on xerotic skin
C Lee, M Russell and E Ruvolo Johnson & Johnson, Skillman, NJ
Glycerin has been shown to have a wide range of benefits to the skin when topically applied to
xerotic skin, such as improving barrier function and skin humectancy. Glycerin acts as a humec-
tant, by binding six molecules of water to one molecule of glycerin minimizing water loss in the
stratum corneum. Glycerin has also been shown to be a lipid-phase modulator, inhibiting the tran-
sition of stratum corneum lipids from liquid to solid crystals. One area that is not well understood
is the effect of glycerin on proliferation. In the current study we investigated the effects of topical
glycerin on keratinocyte proliferation as well as the barrier properties in subjects with dry skin. In
a 3 week, round-robin, blinded clinical study, the skin dryness benefits of glycerin were evaluated
on African-American and Caucasian women. Subjects applied the products twice a day to the lower
leg after a one week wash out period. The skin hydration properties were assessed by measuring
skin conductance (Skicon 200, I.B.S CO. LTD, Japan), trans-epidermal water loss (Vapometer, Delfin
Technologies, Finland), flaking (D-squames, CuDerm, USA), and proliferation (SkinScan). Evalua-
tions were conducted at baseline and three weeks after treatment. Glycerin significantly increased
skin conductance, reduced trans-epidermal water loss and reduced the desquamation index. Addi-
tionally, glycerin significantly decreased proliferation when compared to baseline, suggesting that
a hyperproliferation state had existed when the skin was dry at baseline and through the use of a
humectant, the proliferation rate was returned to a normal healthy skin level. Taken together these
results demonstrate that glycerin can acutely restore skin moisture and barrier properties while mod-
ulating the hyperproliferation present in dry skin.
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Development of an automatic lesion counting program with digital image processing: An
objective and reproducible method for the evaluation of acne severity
D Suh,1,2 S Min,1,2 H Kong,3 C Yoon3 and H Kim3 1 Dermatology, Seoul National University
College of Medicine, Seoul, Republic of Korea, 2 Acne Research Laboratory, Seoul National
University Hospital, Seoul, Republic of Korea and 3 Department of Biomedical Engineering,
Seoul National University College of Medicine, Seoul, Republic of Korea
Due to the polymorphic and dynamic nature of acne, evaluation of acne severity is difficult. More-
over, there have been several drawbacks in the use of various acne evaluation tools. Some acne
grading methods, which depend on overall impression, require a long training period and there is
a high degree of variability among raters. The use of lesion count provides fair reproducibility but
the method is time consuming. With the use of digital imaging, we have developed ideal image
acquisition conditions that utilize cold cathode fluorescent lamp. We adopted the conditions to
optimize characterization of acne lesions enough to analyze with a computer. Automated lesion
counting for five subtypes of acne (papule, nodule, pustule, whitehead comedone and blackhead
comedone) was performed. The usefulness of the automatic lesion count program was assessed by
a comparison with manual counting and Leeds acne grading system performed by expert derma-
tologists. The sensitivity and specificity of the lesion-counting program was greater than 70% for
papules, nodules, pustules and whitehead comedone. In a comparison with manual counting,
findings with the use of the lesion-counting program were well correlated for papules, nodules, pus-
tules and whitehead comedone (r>0.9). We suggest that this method could be a useful approach to
evaluate the severity of acne.
566
Aquabeautine XL, a novel, marine-derived, self-limiting enzyme providing effective, gentle
exfoliation and clinically demonstrated anti-aging benefits
M Anthonavage,1 S Jindal,1 A Lindberg2 and F Coste2 1 Presperse, Somerset, NJ and 2 Aqua
Biotechnologies, Bergan, Norway
The aim of this presentation is to demonstrate the effectiveness of Aquabeautine XLTM as an supe-
rior skin care technology for a variety of skin conditions resulting from an excess of cornfield skin
resulting in healthier looking more luminous skin. Aquabeautine XLTM is a novel patented marine
ingredient sourced from a protein solution derived from the hatching water of salmon roe. The effects
of Aquabeautine XLTM on human skin were discovered by coincidence when salmon hatchery
workers reported that their hands became soft after sorting salmon eggs despite their prolonged
exposure to cold water. After further investigation, the constituents of this water were identified as
a mixture of proteases and polypeptides by which the actions on the human skin are discussed.
Through in vitro testing using skin equivalent models, we are able to show that Aquabeautine XLTM
demonstrates safe and effective ‘smart’ exfoliation properties versus traditionally used technologies
like glycolic acid and bromelain. Interestingly, the properties of the protease allow it to only digest
specific peptides found in desquamating corneocytes leaving living cells unaffected. Clinically, we
have demonstrated that when Aquabeautine XLTM is formulated into traditional emulsion systems,
it is effective at providing significant anti-aging and anti-inflammatory benefits. In separate studies,
Aquabeautine XLTM demonstrates noticeable amelioration of erythema due to sun exposure and
inflammation due to acne. The overall mechanism in which Aquabeautine XLTM works is prima-
rily through by selective removal of dead cells from the outer layer of skin initiating and accelerat-
ing the renewal and healing process while providing safe and effective exfoliation without initiat-
ing the inflammation associated with commonly used acids and enzymes.
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Breast implant associated ALCL – a unique entity in the spectrum of CD30+ LPD
S Story and LJ Geskin Dermatology, University of Pittsburgh School of Medicine, Pittsburgh,
PA
CD30+ lymphoproliferative disorders (LPD) represent a spectrum of diseases ranging from lym-
phomatoid papulosis to systemic nodal ALCL. These LPDs have distinct clinical phenotype and prog-
nosis. In January 2011, FDA announced a possible association between saline and silicone gel-filled
breast implants and ALCL, which was likened to the systemic ALCL and treated accordingly (mainly
with CHOP chemotherapy +/- radiation therapy). Considering, that various CD30+ lymphomas have
been described in association with different stimuli, including arthropod bites, drugs, metallic ortho-
pedic implant, we hypothesized that breast implant associated ALCL (iALCL) may represent a dis-
tinct entity, different from systemic lymphoma. Our systematic review of scientific literature pub-
lished between 1990 and 2012 as well as all available electronic sources, including 26 unique cases
of iALCL reported at the FDA website, revealed that these lymphomas represent a distinctive sub-
set of the CD30 LPD. There are several unique features iALCL which put them apart from systemic
ALCL: 1) they demonstrate indolent course and excellent prognosis (only one death reported) despite
of their Alk- status, similar to primary cutaneous indolent ALK- ALCL with an overall 5 year survival
of 90%. This is in stark contrast to systemic ALK- ALCL with an overall 5-year survival rate of
approximately 40%; 2) their course points toward their reactive nature – spontaneous remission
after removal of the implant and very strong association with seroma have been reported. Seroma
was present in majority of the cases where the records were available. In contrast, incidence of
seroma after any breast augmentations is only 0.05-0.1%. In conclusion, our literature review revealed
that iALCL may represent a separate from systemic lymphoma entity. As such, breast implant removal
should be recommended immediately if such lymphoma is suspected. In addition, women with
seroma should be monitored closely for ALCL development. There is not enough information to pro-
vide treatment recommendations, but conservative approach may be warranted.
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